Purpose
After surgery for lung adenocarcinoma, a patient may experience various states of recurrence, with multiple factors potentially influencing the transitions between these states. Our purpose was to investigate the effects of clinical and pathological factors on tumor recurrence, death, and prognosis across various metastasizing pathways.
Materials and Methods
Our study group included 335 patients with all demographic and pathologic data available who underwent surgical resection for lung adenocarcinoma for more than 10 years. The following states of disease were defined: initial state, operation (OP); three intermediate states of local recurrence (LR), metastasis (Meta), and concurrent LR with metastasis (LR+Meta); and a terminal state, death. We identified 8 transitions representing various pathways of tumor progression. We employed a multi-state model (MSM) to separate the impacts of multiple prognostic factors on the transitions following surgery.
Results
After surgery, approximately half of patients experienced recurrence. Specifically, 142 (42.4%), 54 (16.1%), and 7 (2.1%) patients developed Meta, LR+Meta, and LR, respectively. Clinical and pathological factors associated with the transitions were different. Impact of pathological lymph node remained a risk factor for both OP to Meta (λ02, p-value=0.001) and OP to LR+Meta (λ03, p-value = 0.001).
Conclusion
Lung adenocarcinoma displays a broad spectrum of clinical scenarios even after curative surgery. Incidence, risk factors, and prognosis varied across different pathways of recurrence in lung adenocarcinoma patients. The greatest implication of this MSM is its ability to predict the timing and type of clinical intervention that will have the greatest impact on survival.
Choong-kun Lee, Jeong Min Choo, Yong Chan Ahn, Jin Kim, Sun Young Rha, Chai Hong Rim, On behalf of the 50th Anniversary Committee of the Korean Cancer Association
Cancer Res Treat. 2025;57(1):11-18. Published online December 5, 2024
During the celebration of the 50th anniversary of the founding of the Korean Cancer Association, articles published in Cancer Research and Treatment from 2004 to 2023 were assessed based on the subject and design of each study. Based on this analysis, trends in domestic cancer research were inferred and directions were suggested for the future development of Cancer Research and Treatment.
Purpose
To investigate the potential role of low‒dose cyclophosphamide (Cy) as a radiosensitizer by evaluating its impact on the immune response and the abscopal effect of stereotactic ablative radiotherapy (SABR) through preclinical models.
Materials and Methods
CT26 tumors (immunologically hot) and 4T1 tumors (immunologically cold), grown in immunocompetent BALB/c and immunodeficient BALB/c‒nude mice, were irradiated with 20 Gy in two fractions with 5‒day spacing followed by intraperitoneal injections of 9 mg/kg Cy every 3 days. Immunological changes in CT26 tumors caused by the treatments were assessed using flow cytometry. Changes in the expression of HIF‒1α in tumors were also assessed. Splenocytes and bone marrow‒derived dendritic cells (DCs) were exposed to various concentrations of Cy to assess T cell proliferation and DC differentiation.
Results
The combination of Cy with RT (RT+Cy) significantly suppressed tumor growth compared to RT alone in immunocompetent mice, while that effect was not observed in immunodeficient mice. Additionally, RT+Cy effectively induced abscopal effects in hot and cold tumors, with increased CD8+ T cells in blood and tumors. Significantly higher expression levels of Granzyme B, IFN‒γ, and TNF‒α were observed in RT+Cy group compared to the RT alone group. In vitro data indicated that low‒dose Cy promotes DC differentiation. Low‒dose Cy suppressed the radiation‒induced upregulation of HIF‒1α in the tumors.
Conclusion
Low‒dose Cy enhances tumoricidal effects of 5‒day spacing high‒dose RT by increasing anti-tumor immune responses.
Purpose Major pathologic response (MPR), defined as ≤ 10% of residual viable tumor (VT), is a prognostic factor in non–small cell lung cancer (NSCLC) after neoadjuvant therapy. This study evaluated interobserver reproducibility in assessing MPR, compared area-weighted and unweighted VT (%) calculation, and determined optimal VT (%) cutoffs across histologic subtypes for survival prediction.
Materials and Methods This retrospective study included 108 patients with NSCLC who underwent surgical resection after neoadjuvant chemotherapy or chemoradiation at Seoul National University Bundang Hospital between 2009-2018. Three observers with varying expertise independently assessed tumor bed and VT (%) based on digital whole-slide images.
Results Reproducibility in tumor bed delineation was reduced in squamous cell carcinoma (SqCC) with smaller tumor bed, although overall concordance was high (Dice coefficient, 0.96; intersection-over-union score, 0.92). Excellent agreement was achieved for VT (%) (intraclass correlation coefficient=0.959) and MPR using 10% cutoff (Fleiss’ kappa=0.911). Shifting between area-weighted and unweighted VT (%) showed only one case differing in MPR status out of 81 cases. The optimal cutoff was 10% for both adenocarcinoma (ADC) and SqCC. MPR+ was observed in 18 patients (17%), with SqCC showing higher MPR+ rates (p=0.044), lower VT (%) (p < 0.001), and better event-free survival (p=0.015) than ADC. MPR+ significantly improved overall survival (p=0.023), event-free survival (p=0.001), and lung cancer-specific survival (p=0.012).
Conclusion While MPR assessment demonstrated robust reproducibility with minimal impact from the tumor bed, attention is warranted when evaluating smaller tumor beds in SqCC. A 10% cutoff reliably predicted survival across histologic subtypes with higher interobserver reproducibility.
Purpose Extranodal natural killer/T-cell lymphoma (ENKTL) predominantly manifests in East Asia and Latin America. Despite shared intrinsic factors, such as ethnic and genetic backgrounds, the progression of ENKTL can be influenced by extrinsic factors related to changing lifestyle patterns.
Materials and Methods This study collected stool samples from newly diagnosed (ND)–ENKTL patients (n=40) and conducted whole genome shotgun sequencing.
Results ND-ENKTL revealed reduced alpha diversity in ND-ENKTL compared to healthy controls (HCs) (p=0.008), with Enterobacteriaceae abundance significantly contributing to the beta diversity difference between ENKTL and HCs (p < 0.001). Functional analysis indicated upregulated aerobic metabolism and degradation of aromatic compounds in ND-ENKTL. Enterobacteriaceae were associated not only with clinical data explaining disease status (serum C-reactive protein, stage, prognosis index of natural killer cell lymphoma [PINK], and PINK-E) but also with clinical outcomes (early relapse and short progression-free survival). The relative abundance of Enterobacteriaceae at the family level was similar between ENKTL and diffuse large B-cell lymphoma (DLBCL) (p=0.140). However, the ENKTL exhibited a higher abundance of Escherichia, in contrast to the prevalence of Enterobacter and Citrobacter in DLBCL. Linear regression analysis demonstrated a significant association between Escherichia abundance and programmed cell death-ligand-1 (PD-L1) levels in tissue samples (p=0.025), whereas no correlation with PD-L1 was observed for Enterobacteriaceae at the family level (p=0.571).
Conclusion ND-ENKTL exhibited an abundance of Enterobacteriaceae and a dominant presence of Escherichia. These microbial characteristics correlated with disease status, treatment outcomes, and PD-L1 expression, suggesting the potential of the ENKTL microbiome as a biomarker and cause of lymphomagenesis, which warrants further exploration.
Purpose Given that 40%-50% of primary central nervous system lymphoma (PCNSL) tissues exhibit aberrancy on 9p24.1, immune checkpoint inhibitors (ICI) may work for the disease.
Materials and Methods To define the role of ICIs in PCNSL, we carried out a nationwide retrospect analysis for 22 patients who had been treated with nivolumab monotherapy for relapsed or refractory PCNSL.
Results The median age at diagnosis was 66, and male: female ratio was 1:1. Patients received nivolumab after a median of 3 lines (range, 2 to 6) of therapy and at the median age of 67 years (range, 37 to 82 years). Eleven patients (50%) were refractory to the last treatment prior to nivolumab. With a median follow-up duration of 22.3 months (95% confidence interval [CI], 13.1 to 31.5), nine patients (41%) had an objective response (6 complete responses, 3 partial responses), and the median duration of response was 20.9 months (95% CI, 1.7 to 40.0). The median progression-free survival and overall survival were 2.1 months (95% CI, 0.2 to 4.0) and 18.9 months (95% CI, 5.0 to 32.8), respectively. Nivolumab was generally well-tolerated as no patients required dose reduction and only two patients required delay of treatment.
Conclusion Our study suggests that nivolumab can be a reasonable option with the durable response for RR PCNSL.
Yoon Seok Choi, Joonho Shim, Ka-Won Kang, Sang Eun Yoon, Jun Sik Hong, Sung Nam Lim, Ho-Young Yhim, Jung Hye Kwon, Gyeong-Won Lee, Deok-Hwan Yang, Sung Yong Oh, Ho-Jin Shin, Hyeon-Seok Eom, Dok Hyun Yoon, Hong Ghi Lee, Seong Hyun Jeong, Won Seog Kim, Seok Jin Kim
Cancer Res Treat. 2025;57(1):267-279. Published online July 16, 2024
Purpose This multicenter, open-label, phase II trial evaluated the efficacy and safety of bortezomib combined with dexamethasone for the treatment of relapsed/refractory cutaneous T-cell lymphoma (CTCL) in previously treated patients across 14 institutions in South Korea.
Materials and Methods Between September 2017 and July 2020, 29 patients with histologically confirmed CTCL received treatment, consisting of eight 4-week cycles of induction therapy followed by maintenance therapy, contingent upon response, for up to one year. The primary endpoint was the proportion of patients achieving an objective global response.
Results Thirteen of the 29 patients (44.8%) achieved an objective global response, including two complete responses. The median progression-free survival (PFS) was 5.8 months, with responders showing a median PFS of 14.0 months. Treatment-emergent adverse events were generally mild, with a low incidence of peripheral neuropathy and hematologic toxicities. Despite the trend toward shorter PFS in patients with higher mutation burdens, genomic profiling before and after treatment showed no significant emergence of new mutations indicative of disease progression.
Conclusion This study supports the use of bortezomib and dexamethasone as a viable and safe treatment option for previously treated CTCL, demonstrating substantial efficacy and manageability in adverse effects. Further research with a larger cohort is suggested to validate these findings and explore the prognostic value of mutation profiles.
Sangwon Lee, Yeon Ho Choi, Hak Min Kim, Min Ah Hong, Phillip Park, In Hae Kwak, Ye Ji Kang, Kui Son Choi, Hyun-Joo Kong, Hyosung Cha, Hyun-Jin Kim, Kwang Sun Ryu, Young Sang Jeon, Hwanhee Kim, Jip Min Jung, Jeong-Soo Im, Heejung Chae
Cancer Res Treat. 2025;57(1):19-27. Published online July 15, 2024
The common data model (CDM) has found widespread application in healthcare studies, but its utilization in cancer research has been limited. This article describes the development and implementation strategy for Cancer Clinical Library Databases (CCLDs), which are standardized cancer-specific databases established under the Korea-Clinical Data Utilization Network for Research Excellence (K-CURE) project by the Korean Ministry of Health and Welfare. Fifteen leading hospitals and fourteen academic associations in Korea are engaged in constructing CCLDs for 10 primary cancer types. For each cancer type-specific CCLD, cancer data experts determine key clinical data items essential for cancer research, standardize these items across cancer types, and create a standardized schema. Comprehensive clinical records covering diagnosis, treatment, and outcomes, with annual updates, are collected for each cancer patient in the target population, and quality control is based on six-sigma standards. To protect patient privacy, CCLDs follow stringent data security guidelines by pseudonymizing personal identification information and operating within a closed analysis environment. Researchers can apply for access to CCLD data through the K-CURE portal, which is subject to Institutional Review Board and Data Review Board approval. The CCLD is considered a pioneering standardized cancer-specific database, significantly representing Korea’s cancer data. It is expected to overcome limitations of previous CDMs and provide a valuable resource for multicenter cancer research in Korea.
Citations
Citations to this article as recorded by
Predictive Mortality and Gastric Cancer Risk Using Clinical and Socio-Economic Data: A Nationwide Multicenter Cohort Study Seong Uk Kang, Seung-Joo Nam, Oh Beom Kwon, Inhyeok Yim, Tae-Hoon Kim, Na Young Yeo, Myoung Nam Lim, Woo Jin Kim, Sang Won Park Cancers.2024; 17(1): 30. CrossRef
Hee Young Ju, Na Hee Lee, Eun Sang Yi, Young Bae Choi, So Jin Kim, Ju Kyung Hyun, Hee Won Cho, Jae Kyung Lee, Ji Won Lee, Ki Woong Sung, Hong Hoe Koo, Keon Hee Yoo
Cancer Res Treat. 2025;57(1):240-249. Published online July 5, 2024
Purpose Hematopoietic stem cell transplantation (HSCT) has been an important method of treatment in the advance of pediatric acute lymphoblastic leukemia (ALL). The indications for HSCT are evolving and require updated establishment. In this study, we aimed to investigate the efficacy of HSCT on the treatment outcome of pediatric ALL, considering the indications for HSCT and subgroups.
Materials and Methods A retrospective analysis was conducted on ALL patients diagnosed and treated at a single center. Risk groups were categorized based on age at diagnosis, initial white blood cell count, disease lineage (B/T), and cytogenetic study results. Data on the patients’ disease status at HSCT and indications of HSCT were collected. Indications for HSCT were categorized as upfront HSCT at 1st complete remission, relapse, and refractory disease.
Results Among the 549 screened patients, a total of 418 patients were included in the study; B-cell ALL (n=379) and T-cell ALL (T-ALL) (n=39). HSCT was conducted on a total of 106 patients (25.4%), with a higher frequency as upfront HSCT in higher-risk groups and specific cytogenetics. The overall survival (OS) was significantly better when done upfront than in relapsed or refractory state in T-ALL patients (p=0.002). The KMT2A-rearranged ALL patients showed superior event-free survival (p=0.002) and OS (p=0.022) when HSCT was done as upfront treatment.
Conclusion HSCT had a substantial positive effect in a specific subset of pediatric ALL. In particular, frontline HSCT for T-ALL and KMT2A-rearranged ALL offered a better prognosis than when HSCT was conducted in a relapsed or refractory setting.
Dong-Woo Choi, Min Yeong Guk, Hye Ri Kim, Kwang Sun Ryu, Hyun-Joo Kong, Hyo Soung Cha, Hyun-Jin Kim, Heejung Chae, Young Sang Jeon, Hwanhee Kim, Jipmin Jung, Jeong-Soo Im, Kui Son Choi
Cancer Res Treat. 2024;56(4):1014-1026. Published online April 30, 2024
This paper provides a comprehensive overview of the Cancer Public Library Database (CPLD), established under the Korean Clinical Data Utilization for Research Excellence project (K-CURE). The CPLD links data from four major population-based public sources: the Korea National Cancer Incidence Database in the Korea Central Cancer Registry, cause-of-death data in Statistics Korea, the National Health Information Database in the National Health Insurance Service, and the National Health Insurance Research Database in the Health Insurance Review & Assessment Service. These databases are linked using an encrypted resident registration number. The CPLD, established in 2022 and updated annually, comprises 1,983,499 men and women newly diagnosed with cancer between 2012 and 2019. It contains data on cancer registration and death, demographics, medical claims, general health checkups, and national cancer screening. The most common cancers among men in the CPLD were stomach (16.1%), lung (14.0%), colorectal (13.3%), prostate (9.6%), and liver (9.3%) cancers. The most common cancers among women were thyroid (20.4%), breast (16.6%), colorectal (9.0%), stomach (7.8%), and lung (6.2%) cancers. Among them, 571,285 died between 2012 and 2020 owing to cancer (89.2%) or other causes (10.8%). Upon approval, the CPLD is accessible to researchers through the K-CURE portal. The CPLD is a unique resource for diverse cancer research to investigate medical use before a cancer diagnosis, during initial diagnosis and treatment, and long-term follow-up. This offers expanded insight into healthcare delivery across the cancer continuum, from screening to end-of-life care.
Citations
Citations to this article as recorded by
Risk Factors and Prevention of Stomach Cancer, Excluding Helicobacter pylori Seung-Woo Lee The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2024; 24(3): 243. CrossRef
Prediction model for survival of younger patients with breast cancer using the breast cancer public staging database Ha Ye Jin Kang, Minsam Ko, Kwang Sun Ryu Scientific Reports.2024;[Epub] CrossRef
Predictive Mortality and Gastric Cancer Risk Using Clinical and Socio-Economic Data: A Nationwide Multicenter Cohort Study Seong Uk Kang, Seung-Joo Nam, Oh Beom Kwon, Inhyeok Yim, Tae-Hoon Kim, Na Young Yeo, Myoung Nam Lim, Woo Jin Kim, Sang Won Park Cancers.2024; 17(1): 30. CrossRef
Seung-been Lee, Ji-Won Kim, Hong-Geun Kim, Sung-Hyun Hwang, Kui-Jin Kim, Ju Hyun Lee, Jeongmin Seo, Minsu Kang, Eun Hee Jung, Koung Jin Suh, Se Hyun Kim, Jin Won Kim, Yu Jung Kim, Jee Hyun Kim, Nak-Jung Kwon, Keun-Wook Lee
Cancer Res Treat. 2024;56(4):1171-1182. Published online April 29, 2024
Purpose This study aimed to compare tumor tissue DNA (ttDNA) and circulating tumor DNA (ctDNA) to explore the clinical applicability of ctDNA and to better understand clonal evolution in patients with metastatic colorectal cancer undergoing palliative first-line systemic therapy.
Materials and Methods We performed targeted sequencing analysis of 88 cancer-associated genes using germline DNA, ctDNA at baseline (baseline-ctDNA), and ctDNA at progressive disease (PD-ctDNA). The results were compared with ttDNA data.
Results Among 208 consecutively enrolled patients, we selected 84 (41 males; median age, 59 years; range, 35 to 90 years) with all four sample types available. A total of 202 driver mutations were found in 34 genes. ttDNA exhibited the highest mutation frequency (n=232), followed by baseline-ctDNA (n=155) and PD-ctDNA (n=117). Sequencing ctDNA alongside ttDNA revealed additional mutations in 40 patients (47.6%). PD-ctDNA detected 13 novel mutations in 10 patients (11.9%) compared to ttDNA and baseline-ctDNA. Notably, seven mutations in five patients (6.0%) were missense or nonsense mutations in APC, TP53, SMAD4, and CDH1 genes. In baseline-ctDNA, higher maximal variant allele frequency (VAF) values (p=0.010) and higher VAF values of APC (p=0.012), TP53 (p=0.012), and KRAS (p=0.005) mutations were significantly associated with worse overall survival.
Conclusion While ttDNA remains more sensitive than ctDNA, our ctDNA platform demonstrated validity and potential value when ttDNA was unavailable. Post-treatment analysis of PD-ctDNA unveiled new pathogenic mutations, signifying cancer’s clonal evolution. Additionally, baseline-ctDNA’s VAF values were prognostic after treatment.
Youjin Kim, Bhumsuk Keam, Eun Joo Kang, Jin-Soo Kim, Hye Ryun Kim, Keun-Wook Lee, Jung Hye Kwon, Kyoung Eun Lee, Yaewon Yang, Yoon Hee Choi, Min Kyoung Kim, Jun Ho Ji, Tak Yun, Moon Young Choi, Ki Hyeong Lee, Sung-Bae Kim, Myung-Ju Ahn
Cancer Res Treat. 2024;56(4):1068-1076. Published online April 15, 2024
Purpose In this study, we evaluated 66 patients diagnosed with adenoid cystic carcinoma (ACC) enrolled in two Korean Cancer Study Group trials to investigate the response and progression patterns in recurrent and/or metastatic ACC treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs).
Materials and Methods We evaluated 66 patients diagnosed with ACC who were enrolled in the Korean Cancer Study Group trials. The tumor measurements, clinical data, treatment outcomes, and progression patterns of therapy were analyzed.
Results In the 66 patients (53 receiving axitinib and 13 receiving nintedanib), the disease control rate was 61%, and three patients achieved partial response. The median follow-up, median progression-free survival (PFS), overall survival, and 6-month PFS rate were 27.6%, 12.4%, and 18.1% months and 62.1%, respectively. Among 42 patients who experienced progression, 27 (64.3%) showed target lesion progression. Bone metastasis was an independent poor prognostic factor.
Conclusion Overall, most patients demonstrated stable disease with prolonged PFS; however, prominent target lesion progression occurred in some patients. Thus, PFS may capture VEGFR-TKI efficacy better than the objective response rate.
Eun Hye Park, Kyu-Won Jung, Nam Ju Park, Mee Joo Kang, E Hwa Yun, Hye-Jin Kim, Jeong-Eun Kim, Hyun-Joo Kong, Jeong-Soo Im, Hong Gwan Seo, The Community of Population-Based Regional Cancer Registries
Cancer Res Treat. 2024;56(2):357-371. Published online March 13, 2024
Purpose The current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in 2021.
Materials and Methods Incidence, survival, and prevalence rates of cancer were calculated using the Korea National Cancer Incidence Database, from 1999 to 2021, with survival follow-up until December 31, 2022. Deaths from cancer were assessed using causes-of-death data obtained from Statistics Korea.
Results The number of new cancer diagnoses in 2021 increased by 27,002 cases (10.8%) compared to 2020. In 2021, newly diagnosed cancer cases and deaths from cancer were reported as 277,523 (age-standardized rate [ASR], 289.3 per 100,000) and 82,688 (ASR, 67.6 per 100,000), respectively. The overall cancer incidence rates increased by 3.3% annually from 1999 to 2012, and decreased by 5.3% from 2012 to 2015, thereafter, followed by non-significant changes. Cancer mortality rates have been decreasing since 2002, with more rapid decline in recent years (annual decrease of 2.8% from 2002 to 2013; 3.2% from 2013 to 2021). The 5-year relative survival between 2017 and 2021 was 72.1%, which contributed to prevalent cases reaching over 2.4 million in 2021.
Conclusion In 2021, the number of newly diagnosed cancer patients increased as healthcare utilization recovered from the coronavirus disease 2019–related declines of 2020. Revised cancer registration guidelines expanded the registration scope, particularly for stomach and colorectal cancer. Survival rates have improved over the years, leading to a growing population of cancer survivors, necessitating a comprehensive cancer control strategy. The long-term impact of the pandemic on cancer statistics requires future investigation.
Citations
Citations to this article as recorded by
Survivorship concerns among posttreatment cancer survivors in South Korea: A secondary analysis of a cross-sectional survey Soo Hyun Kim International Journal of Nursing Studies.2025; 162: 104982. CrossRef
Risk of malignant lymphoma in patients with previous tuberculosis infection: a cohort study Yun-Gyoo Lee, Dayeon Seo, Hyun-Il Gil, Dong-Hoe Koo, Suk Joong Oh Annals of Hematology.2025;[Epub] CrossRef
Korean Practice Guidelines for Gastric Cancer 2024: An Evidence-based, Multidisciplinary Approach (Update of 2022 Guideline) In-Ho Kim, Seung Joo Kang, Wonyoung Choi, An Na Seo, Bang Wool Eom, Beodeul Kang, Bum Jun Kim, Byung-Hoon Min, Chung Hyun Tae, Chang In Choi, Choong-kun Lee, Ho Jung An, Hwa Kyung Byun, Hyeon-Su Im, Hyung-Don Kim, Jang Ho Cho, Kyoungjune Pak, Jae-Joon Kim Journal of Gastric Cancer.2025; 25(1): 5. CrossRef
Sex Differences in Clinical Features and Survival Outcomes of Esophageal Cancer: A Comparative Study in the Korean Population Jin Hee Noh, Hyungchul Park, Do Hoon Kim, Hee Kyong Na, Ji Yong Ahn, Jeong Hoon Lee, Kee Wook Jung, Kee Don Choi, Ho June Song, Gin Hyug Lee, Hwoon-Yong Jung The World Journal of Men's Health.2025;[Epub] CrossRef
Factors Influencing Postoperative Quality of Life in Korean Brain Tumor Survivors Soomin Lim, Smi Choi-Kwon Journal of Neuroscience Nursing.2025;[Epub] CrossRef
Colorectal Cancer Survivors' Inner Strength, Multiple Identities, and Quality of Life by Gender and Ostomy Presence: A Cross-Sectional Study Hannah Yu, Eunjung Ryu Korean Journal of Adult Nursing.2024; 36(2): 171. CrossRef
Chuna Manual Therapy or Electroacupuncture with Pregabalin for Chemotherapy-Induced Peripheral Neuropathy: A Randomized Controlled Pilot Study Yeon-Woo Lee, Ilkyun Lee, Jin-Hyun Lee, Min-Geun Park, Ji-Hoon Kim, Yoon-Young Sunwoo, Man-Suk Hwang, Tae-Yong Park Journal of Clinical Medicine.2024; 13(13): 3916. CrossRef
SMARCD3 Overexpression Promotes Epithelial–Mesenchymal Transition in Gastric Cancer Sun Yi Park, Ji-Ho Park, Jung Wook Yang, Eun-Jung Jung, Young-Tae Ju, Chi-Young Jeong, Ju-Yeon Kim, Taejin Park, Tae-Han Kim, Miyeong Park, Young-Joon Lee, Sang-Ho Jeong Cancers.2024; 16(12): 2282. CrossRef
Factors influencing psychological distress among breast cancer survivors using machine learning techniques Jin-Hee Park, Misun Chun, Sun Hyoung Bae, Jeonghee Woo, Eunae Chon, Hee Jun Kim Scientific Reports.2024;[Epub] CrossRef
The Influence of Professional Self-Concept and Patient Safety Culture on Burnout among Nurses in a Cancer Hospital Soyoon Do, Eunjung Ryu Asian Oncology Nursing.2024; 24(2): 53. CrossRef
Prognostic Impact of Reactive Oxygen Species Modulator 1 in Surgically Resected Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinomas Tae-Woo Kim, Kiyong Na, Junyang Jung, Heejin Lim, Hyewon Seo, Seung Hyeun Lee Oncology.2024; 102(11): 969. CrossRef
Performance of the National Cancer Screening Program for Gastric Cancer in Korea Young-Il Kim The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2024; 24(3): 231. CrossRef
Sites of Metastasis and Survival in Metastatic Renal Cell Carcinoma: Results From the Korean Renal Cancer Study Group Database Chan Ho Lee, Minyong Kang, Cheol Kwak, Young Hwii Ko, Jung Kwon Kim, Jae Young Park, Seokhwan Bang, Seong Il Seo, Jungyo Suh, Wan Song, Cheryn Song, Hyung Ho Lee, Jinsoo Chung, Chang Wook Jeong, Jung Ki Jo, Seock Hwan Choi, Joongwon Choi, Changil Choi, Se Journal of Korean Medical Science.2024;[Epub] CrossRef
Evolving trends in treatment patterns for hepatocellular carcinoma in Korea from 2008 to 2022: a nationwide population-based study Ji Won Han, Won Sohn, Gwang Hyeon Choi, Jeong Won Jang, Gi Hyeon Seo, Bo Hyun Kim, Jong Young Choi Journal of Liver Cancer.2024; 24(2): 274. CrossRef
Redefining the role of radiation therapy in pancreatic cancer management: innovations and future directions: A narrative review Jeong Il Yu Precision and Future Medicine.2024; 8(3): 74. CrossRef
A 5-Year Mortality Prediction Model for Prostate Cancer Patients Based on the Korean Nationwide Health Insurance Claims Database Joungyoun Kim, Yong-Hoon Kim, Yong-June Kim, Hee-Taik Kang Journal of Personalized Medicine.2024; 14(10): 1058. CrossRef
Longitudinal trajectories of frailty and cognitive decline among older Korean cancer survivors Ran Won, Heesook Son, Jeehee Han, Youn-Jung Son Geriatric Nursing.2024; 60: 636. CrossRef
Breast Cancer Statistics in Korea, 2021 Chihwan David Cha, Chan Sub Park, Hee-Chul Shin, Jaihong Han, Jung Eun Choi, Joo Heung Kim, Kyu-Won Jung, Sae Byul Lee, Sang Eun Nam, Tae In Yoon, Young-Joon Kang, Zisun Kim, So-Youn Jung, Hyun-Ah Kim Journal of Breast Cancer.2024; 27(6): 351. CrossRef
Tobacco Use in Korea: Current Epidemiology and Public Health Issues Jong Eun Park, Woo Min Jeong, Ye Jin Choi, So Young Kim, Kyoung Eun Yeob, Jong Hyock Park Journal of Korean Medical Science.2024;[Epub] CrossRef
Endometrial cancer detected unusually after an ankle fracture secondary to severe anemia in an obese woman with heavy menstrual bleeding: A case report Hyung Yoon, Tae Go, Kyung Kim, Yong Song, Dong Suh, Ki Kim Molecular and Clinical Oncology.2024;[Epub] CrossRef
Updates in the 2024 Korean Thyroid Association Clinical Practice Guidelines for Differentiated Thyroid Cancer: from Diagnosis to Initial Treatment Eun Kyung Lee International Journal of Thyroidology.2024; 17(2): 259. CrossRef
Determining risk‐adapted starting age and interval for breast cancer screening based on reproductive and hormonal factors Tung Hoang, Jeonghee Lee, So‐Youn Jung, Jeongseon Kim International Journal of Cancer.2024;[Epub] CrossRef
A Case Study of Korean Medicine in Treating Worsened Esophagitis Symptoms Following Anticancer Therapy in a Patient with Esophageal Cancer Eun-seo Kim, Soo-min Jo, Si-young Song, Geun-jeong Kim, Young-su Lee The Journal of Internal Korean Medicine.2024; 45(5): 895. CrossRef
The Emerging Treatment of BCG (Bacillus Calmette-Guérin)-Unresponsive Non–Muscle-Invasive Bladder Cancer Jong Ho Park, Jong Jin Oh Journal of Urologic Oncology.2024; 22(3): 246. CrossRef
Adherence to the Cancer Prevention Recommendations from World Cancer Research Fund/American Institute for Cancer Research After Cancer Diagnosis on Mortality in South Korea Donghyun Won, Jeeyoo Lee, Sooyoung Cho, Ji Yoon Baek, Daehee Kang, Aesun Shin Nutrients.2024; 16(23): 4049. CrossRef
Trends in Thyroid Cancer Mortality Rates in Korea: Insights from National Health Database Won Gu Kim Endocrinology and Metabolism.2024; 39(6): 853. CrossRef
Impact of Early Oral Feeding on Postoperative Outcomes after Elective Colorectal Surgery: A Systematic Review and Meta-Analysis Soo Young Lee, Eon Chul Han Digestive Surgery.2024; : 1. CrossRef
Nationwide Incidence Trends of Pediatric Parotid Malignancy in Korea and a Retrospective Analysis of Single-Institution Surgical Experience of Parotidectomy Hyun Seong Kim, Seo Young Kim, Eun-Jae Chung, Seong Keun Kwon, Soon-Hyun Ahn, Yuh-Seog Jung, Jungirl Seok Korean Society of Head and Neck Oncology.2024; 40(2): 7. CrossRef
Total gastrectomy patients had a lower diet volume and greater diet frequency than distal gastrectomy patients after 6 months Ye-Ji Kim, Sang-Ho Jeong, Eun-Jung Jung, Taejin Park, Jin-Kwon Lee, Tae-Han Kim, Young-Hye Kim, Jae-Seok Min, Miyeong Park, Young-Joon Lee Medicine.2024; 103(51): e40878. CrossRef
Quality of life outcomes in terminal cancer patients attending regional cancer centers in South Korea: protocol for a prospective cohort study Jung hye Kwon, Jung Hun Kang, Jung-Sik Huh, Su-Jin Koh, Kyu-Hyoung Lim, Byungho Choi, Rock Bum Kim, Young Jin Choi, Eun-Kee Song, Hyun Woo Lee, Ye-Seul Kim, Se-Il Go, Hwan Jung Yun, Sun Jin Sym, Hyewon Ryu, Myung-won Lee BMC Cancer.2024;[Epub] CrossRef
Beyond survival: a comprehensive review of quality of life in rectal cancer patients Won Beom Jung Annals of Coloproctology.2024; 40(6): 527. CrossRef
Purpose This study aimed to report the projected cancer incidence and mortality for the year 2024 to estimate Korea’s current cancer burden.
Materials and Methods Cancer incidence data from 1999 to 2021 were obtained from the Korea National Cancer Incidence Database, and cancer mortality data from 1993 to 2022 were acquired from Statistics Korea. Cancer incidence and mortality were projected by fitting a linear regression model to observed age-specific cancer rates against their respective years and multiplying the projected age-specific rates by the anticipated age-specific population for 2024. A joinpoint regression model was used to determine the year in which the linear trend changed significantly; we only used the data of the latest trend for prediction.
Results In total, 292,221 new cancer cases and 83,770 cancer deaths are expected to occur in Korea in 2024. The most common cancer site is expected to be the thyroid, followed by the colon and rectum, lung, breast, and stomach. These five cancers are expected to represent 55.7% of the overall burden of cancer in Korea. The most common type of cancer leading to death is expected to be lung cancer, followed by liver, colorectal, pancreatic, and stomach cancers.
Conclusion The age-standardized incidence rates for female breast and prostate cancers are estimated to continue to increase. These up-to-date estimates of the cancer burden in Korea could be an important resource for planning and evaluating cancer-control programs.
Citations
Citations to this article as recorded by
Efficacy and safety of herbal medicine treatment on postsurgical recovery in gastric cancer patients: A systematic review and meta-analysis Soo-Dam Kim, Sook-Jin Pyo, Dong-Hyeon Kim, Hwa-Seung Yoo, So-Jung Park Medicine.2025; 104(1): e41034. CrossRef
2023 Update of the Korean Thyroid Association Guidelines for the Management of Thyroid Nodules Eun Kyung Lee, Young Joo Park Clinical Thyroidology®.2024; 36(4): 153. CrossRef
The Role of Local Prostate and Metastasis-Directed Radiotherapy in the Treatment of Oligometastatic Prostate Cancer Seo Hee Choi, Seung-Hoon Beom, Young Deuk Choi, Won Sik Ham, Hyunho Han, Woong Kyu Han, Won Sik Jang, Seung Hwan Lee, Jaeho Cho Cancers.2024; 16(18): 3159. CrossRef
Trend Analysis of Lung Cancer Incidence and Mortality in Xiamen (2011-2020) Jianni Cong, Jiahuang Chi, Junli Zeng, Yilan Lin Risk Management and Healthcare Policy.2024; Volume 17: 2375. CrossRef
The Impact of the Dietary Inflammatory Index, Fasting Blood Glucose, and Smoking Status on the Incidence and Survival of Pancreatic Cancer: A Retrospective Case–Control Study and a Prospective Study Ga Hyun Lee, Yeon Hee Kim, Sang Myung Woo, Woo Jin Lee, Sung-Sik Han, Sang-Jae Park, Sherry Price, Penias Tembo, James R. Hébert, Mi Kyung Kim Nutrients.2024; 16(22): 3941. CrossRef
Purpose The feasibility of sequencing circulating tumor DNA (ctDNA) in plasma as a biomarker to predict early relapse or poor prognosis in patients with follicular lymphoma (FL) receiving systemic immunochemotherapy is not clear.
Materials and Methods We sequenced DNA from cell-free plasma that was serially obtained from newly diagnosed FL patients undergoing systemic immunochemotherapy. The mutation profiles of ctDNA at the time of diagnosis and at response evaluation and relapse and/or progression were compared with clinical course and treatment outcomes.
Results Forty samples from patients receiving rituximab-containing immunochemotherapy were analyzed. Baseline sequencing detected mutations in all cases, with the major detected mutations being KMT2C (50%), CREBBP (45%), and KMT2D (45%). The concentration of ctDNA and tumor mutation burden showed a significant association with survival outcome. In particular, the presence of mutations in CREBBP and TP53 showed poor prognosis compared with patients without them. Longitudinal analysis of ctDNA using serially collected plasma samples showed an association between persistence or reappearance of ctDNA mutations and disease relapse or progression.
Conclusion Analysis of ctDNA mutations in plasma at diagnosis might help predict outcome of disease, while analysis during follow-up may help to monitor disease status of patients with advanced FL. However, the feasibility of ctDNA measurement must be improved in order for it to become an appropriate and clinically relevant test in FL patients.
Citations
Citations to this article as recorded by
Feasibility of Circulating Tumor DNA Detection in the Cerebrospinal Fluid of Patients With Central Nervous System Involvement in Large B-Cell Lymphoma Seok Jin Kim, Jin Ju Kim, Mi Ri Park, Bon Park, Kyung Ju Ryu, Sang Eun Yoon, Won Seog Kim, Saeam Shin, Seung-Tae Lee Annals of Laboratory Medicine.2025; 45(1): 90. CrossRef
Clinical applications of circulating tumor DNA in hematological malignancies: From past to the future Jun-Ying Li, Li-Ping Zuo, Jian Xu, Chun-Yan Sun Blood Reviews.2024; 68: 101237. CrossRef
Molecular Biomarkers in Prediction of High-Grade Transformation and Outcome in Patients with Follicular Lymphoma: A Comprehensive Systemic Review Marie Hairing Enemark, Jonas Klejs Hemmingsen, Maja Lund Jensen, Robert Kridel, Maja Ludvigsen International Journal of Molecular Sciences.2024; 25(20): 11179. CrossRef
Purpose Pulmonary sarcomatoid carcinoma (PSC) is a rare aggressive subtype of non–small cell lung cancer (NSCLC) with limited therapeutic strategies. We attempted to elucidate the evolutionary trajectories of PSC using multiregional and longitudinal tumor samples.
Materials and Methods A total of 31 patients were enrolled in this study and 11 longitudinal samples were available from them. Using whole exome sequencing data, we analyzed the mutational signatures in both carcinomatous and sarcomatous areas in primary tumors of the 31 patients and longitudinal samples obtained from 11 patients. Furthermore, digital droplet polymerase chain reaction (ddPCR), and programmed death-ligand 1 (PD-L1) immunohistochemistry using the Ventana SP263 assay were performed.
Results TP53 was identified as the most frequently altered gene in the primary (74%) and metastatic (73%) samples. MET exon 14 skipping mutations, confirmed by ddPCR, and TP53 mutations were mutually exclusive; whereas, MET exon 14 skipping mutations frequently co-occurred with MDM2 amplification. Metastatic tumors showed dissimilar genetic profiles from either primary component. During metastasis, the signatures of APOBEC decreased in metastatic lesions compared with that in primary lesions. PSC showed higher MET and KEAP1 mutations and stronger PD-L1 protein expression compared with that recorded in other NSCLCs.
Conclusion Decreased APOBEC signatures and subclonal diversity were detected during malignant progression in PSC. Frequent MET mutations and strong PD-L1 expression distinguished PSC from other NSCLCs. The aggressiveness and therapeutic difficulties of PSC were possibly attributable to profound intratumoral and intertumoral genetic diversity. Next-generation sequencing could suggest the appropriate treatment strategy for PSC.
Citations
Citations to this article as recorded by
PD-L1 Expression and Its Modulating Factors in Anaplastic Thyroid Carcinoma Shipra Agarwal, Chan Kwon Jung, Pranitha Gaddam, Mitsuyoshi Hirokawa, Takuya Higashiyama, Jen-Fan Hang, Wei-An Lai, Somboon Keelawat, Zhiyan Liu, Hee Young Na, So Yeon Park, Junya Fukuoka, Shinya Satoh, Zhanna Mussazhanova, Masahiro Nakashima, Kennichi Ka American Journal of Surgical Pathology.2024; 48(10): 1233. CrossRef
Ji Yun Lee, Ji Hyun Kwon, Joon Young Hur, Jun Ho Yi, Ji Hyun Lee, Hyungwoo Cho, Young Rok Do, Jae-Cheol Jo, Hye Jin Kang, Yougil Koh, Won Sik Lee, Sung Nam Lim, Sang Eun Yoon, Seok Jin Kim, Jeong-Ok Lee
Cancer Res Treat. 2024;56(2):681-687. Published online November 10, 2023
Purpose Programmed death-1 blockade with pembrolizumab has shown promising activity in relapsed/refractory (R/R) extranodal natural killer/T-cell lymphoma (NKTCL), but studies are limited, with small patient numbers.
Materials and Methods Thirteen institutes involved with the Consortium for Improving Survival of Lymphoma, a Korean lymphoma study group, collected the clinical data of 59 patients treated with pembrolizumab as salvage therapy between 2016 and 2022.
Results The median age of the patients was 60 years (range, 22 to 87 years), and 76.3% had advanced Ann Abor stage disease. Pembrolizumab was given to 35.6%, 40.7%, and 23.7% of the patients as second-, third-, and fourth- or higher-line chemotherapy, respectively. The overall response rate was 40.7%, with 28.8% having complete response. The estimated 2-year progression-free survival (PFS) and overall survival rates for all patients were 21.5% and 28.7%, respectively; for responders, the rates were 53.0% and 60.7%, respectively. Although not statistically significant, Eastern Cooperative Oncology Group performance status ≥ 2 (hazard ratio [HR], 1.91; 95% confidence interval [95% CI], 0.93 to 3.94; p=0.078) and stage III or IV disease (HR, 2.59; 95% CI, 0.96 to 6.96; p=0.060) were associated with a trend toward shorter PFS in multivariate analysis. Grade 3 or 4 adverse events (AEs) were noted in 12 patients (20.3%); neutropenia (10.2%), fatigue (6.8%), and pneumonitis (5.1%) were most common AEs.
Conclusion In conclusion, while pembrolizumab had a modest effect on patients with R/R NKTCL, it may be a useful salvage therapy for patients with localized disease and good performance status.
Citations
Citations to this article as recorded by
An evaluation of sugemalimab for the treatment of relapsed or refractory extranodal natural killer T-cell lymphoma Yingfang Feng, Xia Liu, Jingwei Yu, Zheng Song, Lanfang Li, Lihua Qiu, Shiyong Zhou, Zhengzi Qian, Xianhuo Wang, Huilai Zhang Expert Opinion on Biological Therapy.2025; 25(1): 9. CrossRef
Purpose Clinical prognostic criteria using preoperative factors were not developed for post–neoadjuvant therapy (NAT) surgery of pancreatic ductal adenocarcinoma (PDAC). We aimed to identify preoperative factors associated with overall survival (OS) in PDAC patients who underwent post-NAT curative-intent surgery and develop risk stratification criteria.
Materials and Methods Consecutive PDAC patients who underwent post-NAT curative-intent surgeries between 2007 and 2020 were retrospectively analyzed. Demographic, laboratory, surgical, and histopathologic variables were collected. Baseline, preoperative, and interval changes of computed tomography (CT) findings proposed by the Society of Abdominal Radiology and the American Pancreatic Association were analyzed. Cox proportional hazard analysis was used to select preoperative variables associated with OS. We developed risk stratification criteria composed of the significant preoperative variables, i.e., post-NAT response criteria. We compared the discrimination performance of post-NAT response criteria with that of post-NAT pathological (yp) American Joint Cancer Committee TNM staging system.
Results One hundred forty-five PDAC patients were included. Stable or increased tumor size on CT (hazard ratio [HR], 2.58; 95% confidence interval [CI], 1.58 to 4.21; p < 0.001) and elevated preoperative carbohydrate antigen 19-9 (CA19-9) level (HR, 1.98; 95% CI, 1.11 to 3.55; p=0.021) were independent factors of OS. The OS of the patient groups stratified by post-NAT response criteria which combined changes in tumor size and CA19-9 showed significant difference (p < 0.001). Such stratification was comparable to ypTNM staging in discrimination performance (difference of C-index, 0.068; 95% CI, –0.012 to 0.142).
Conclusion “Any degree of decrease in tumor size on CT” and CA19-9 normalization or staying normal were independent favorable factors of OS. The combination of the two factors discriminated OS comparably to ypTNM staging.
Purpose Triple-negative breast cancer (TNBC) is a breast cancer subtype that has poor prognosis and exhibits a unique tumor microenvironment. Analysis of the tumor microbiome has indicated a relationship between the tumor microenvironment and treatment response. Therefore, we attempted to reveal the role of the tumor microbiome in patients with TNBC receiving neoadjuvant chemotherapy.
Materials and Methods We collected TNBC patient RNA-sequencing samples from the Gene Expression Omnibus and extracted microbiome count data. Differential and relative abundance were estimated with linear discriminant analysis effect size. We calculated the immune cell fraction with CIBERSORTx and conducted survival analysis using the Cancer Genome Atlas patient data. Correlations between the microbiome and immune cell compositions were analyzed and a prediction model was constructed to estimate drug response.
Results Among the pathological complete response group (pCR), the beta diversity varied considerably; consequently, 20 genera and 24 species were observed to express a significant differential and relative abundance. Pandoraea pulmonicola and Brucella melitensis were found to be important features in determining drug response. In correlation analysis, Geosporobacter ferrireducens, Streptococcus sanguinis, and resting natural killer cells were the most correlated factors in the pCR, whereas Nitrosospira briensis, Plantactinospora sp. BC1, and regulatory T cells were key features in the residual disease group.
Conclusion Our study demonstrated that the microbiome analysis of tumor tissue can predict chemotherapy response of patients with TNBC. Further, the immunological tumor microenvironment may be impacted by the tumor microbiome, thereby affecting the corresponding survival and treatment response.
Citations
Citations to this article as recorded by
Molecular Classification of Breast Cancer Using Weakly Supervised Learning Wooyoung Jang, Jonghyun Lee, Kyong Hwa Park, Aeree Kim, Sung Hak Lee, Sangjeong Ahn Cancer Research and Treatment.2025; 57(1): 116. CrossRef
Shotgun Metagenomics Reveals Minor Micro“bee”omes Diversity Defining Differences between Larvae and Pupae Brood Combs Daniil Smutin, Amir Taldaev, Egor Lebedev, Leonid Adonin International Journal of Molecular Sciences.2024; 25(2): 741. CrossRef
Purpose We intend to evaluate the efficacy of salvage treatments for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) through meta-analysis.
Materials and Methods R/R DLBCL trials were divided into two groups based on eligibility for autologous stem-cell transplantation (ASCT), and meta-analysis of each group was performed. Random effects models were used to estimate the 1-year progression-free survival (PFS) rate, and chimeric antigen receptor (CAR) T-cell therapy was used as reference treatment.
Results Twenty-six ASCT-eligible cohorts from 17 studies comprising 2,924 patients and 59 ASCT-ineligible cohorts from 53 studies comprising 3,617 patients were included in the pooled analysis. In the ASCT-eligible group, the pooled 1-year PFS rate was 0.40 (95% confidence interval [CI], 0.15 to 0.65) for the CAR T-cell group and 0.34 (95% CI, 0.30 to 0.37) for the group with chemotherapy followed by ASCT intention. The two treatments were not significantly different in meta-regression analysis. In the ASCT-ineligible group, the pooled 1-year PFS was 0.40 (95% CI, 0.35 to 0.46) for CAR T-cell, and the highest primary outcome was 0.47 (95% CI, 0.37 to 0.57) for the tafasitamab group. CAR T-cell therapy showed significantly better outcomes than chemotherapy and therapies based on ibrutinib, lenalidomide, and selinexor. However, loncastuximab, polatuzumab plus bendamustine and rituximab, and the tafasitamab group showed no different efficacy than CAR T-cell therapy after adjusting for median number of previous lines of treatment.
Conclusion Although several regimens were crudely grouped for classification, CAR T-cell therapy did not outperform chemotherapy followed by ASCT in the second-line setting or several recently developed agents in the ASCT-ineligible setting.
Citations
Citations to this article as recorded by
Efficacy and safety of polatuzumab-vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: A systematic review and meta-analysis Hanzala Ahmed Farooqi, Muhammad Saffi Ullah, Ahmed Raza, Zain Sadiq, Wardah Ali Shaikh, Rahmah Muhammad, Muhammad Shoaib Hussain Critical Reviews in Oncology/Hematology.2025; 207: 104611. CrossRef
Polatuzumab vedotin combined with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma: A systematic review protocol Mohammadreza Eslami, Mahdi Mehrabi, Mehrdad Payandeh, Fakhredin Saba, Chen Li PLOS ONE.2024; 19(8): e0308247. CrossRef
Real-world effectiveness of chemoimmunotherapy and novel therapies for patients with relapsed/refractory aggressive large B-cell lymphoma Loretta J. Nastoupil, Clark R. Andersen, Amy Ayers, Yucai Wang, Thomas M. Habermann, Dai Chihara, Brad S. Kahl, Brian K. Link, Jean L. Koff, Jonathon B. Cohen, Peter Martin, Izidore S. Lossos, Michele Stanchina, Sara Haddadi, Carla Casulo, Sabarish Ayyapp Clinical Lymphoma Myeloma and Leukemia.2024;[Epub] CrossRef
Clinical scoring systems, molecular subtypes and baseline [18F]FDG PET/CT image analysis for prognosis of diffuse large B-cell lymphoma Zhuxu Sun, Tianshuo Yang, Chongyang Ding, Yuye Shi, Luyi Cheng, Qingshen Jia, Weijing Tao Cancer Imaging.2024;[Epub] CrossRef
Targeting CD22 for B-cell hematologic malignancies Jia Xu, Wenjing Luo, Chenggong Li, Heng Mei Experimental Hematology & Oncology.2023;[Epub] CrossRef
Purpose The aim of the present study was to evaluate the per-lesion sensitivity and specificity of the Korean Liver Cancer Association–National Cancer Center (KLCA-NCC) 2022 criteria for the noninvasive diagnosis of hepatocellular carcinoma (HCC), with intraindividual comparison of the diagnostic performance of magnetic resonance imaging with extracellular agents (ECA-MRI) and hepatobiliary agents (HBA-MRI).
Materials and Methods Patients at high risk for HCC who were referred to a tertiary academic institution for hepatic lesions with size ≥ 10 mm between July 2019 and June 2022 were enrolled. A total of 91 patients (mean age, 58.1 years; 76 men and 15 women) with 118 lesions who underwent both ECA-MRI and HBA-MRI were eligible for final analysis. The per-lesion sensitivities and specificities of the KLCA-NCC 2022 criteria using ECA-MRI and HBA-MRI were compared using McNemar’s test.
Results The 118 lesions were 93 HCCs, 4 non-HCC malignancies, and 21 benign lesions. On HBA-MRI, the “definite” HCC category showed significantly higher sensitivity than ECA-MRI (78.5% vs. 58.1%, p < 0.001), with identical specificity (92.0% vs. 92.0%, p > 0.999). For “probable” or “definite” HCC categories, there were no differences in the sensitivity (84.9% vs. 84.9%, p > 0.999) and specificity (84.0% vs. 84.0%, p > 0.999) between ECA-MRI and HBA-MRI.
Conclusion The “definite” HCC category of the KLCA-NCC 2022 criteria showed higher sensitivity in diagnosing HCC on HBA-MRI compared with ECA-MRI, without compromising specificity. There were no significant differences in the sensitivity and specificity of “probable” or “definite” HCC categories according to ECA-MRI and HBA-MRI.
Citations
Citations to this article as recorded by
Intraindividual comparison of prognostic imaging features of HCCs between MRIs with extracellular and hepatobiliary contrast agents Ja Kyung Yoon, Dai Hoon Han, Sunyoung Lee, Jin‐Young Choi, Gi Hong Choi, Do Young Kim, Myeong‐Jin Kim Liver International.2024; 44(10): 2847. CrossRef
Hyungwoo Cho, Dok Hyun Yoon, Dong-Yeop Shin, Youngil Koh, Sung-Soo Yoon, Seok Jin Kim, Young Rok Do, Gyeong-Won Lee, Jae-Yong Kwak, Yong Park, Min Kyoung Kim, Hye Jin Kang, Jun Ho Yi, Kwai Han Yoo, Won Sik Lee, Byeong Bae Park, Jae Cheol Jo, Hyeon-Seok Eom, Hyo Jung Kim, Seong Hyun Jeong, Young-Woong Won, Byeong Seok Sohn, Ji-Hyun Kwon, Cheolwon Suh, Won Seog Kim
Cancer Res Treat. 2023;55(2):684-692. Published online January 2, 2023
Purpose We conducted a nationwide, multicenter, prospective registry study for newly diagnosed patients with peripheral T-cell lymphoma (PTCL) to better define the clinical characteristics, treatment patterns, survival outcomes, and the role of upfront autologous stem cell transplantation (ASCT) in these patients.
Materials and Methods Patients with PTCL receiving chemotherapy with curative intent were registered and prospectively monitored. All patients were pathologically diagnosed with PTCL.
Results A total of 191 patients with PTCL were enrolled in this prospective registry study. PTCL, not otherwise specified (PTCL-NOS) was the most common pathologic subtype (n=80, 41.9%), followed by angioimmunoblastic T-cell lymphoma (AITL) (n=60, 31.4%). With a median follow-up duration of 3.9 years, the 3-year progression-free survival (PFS) and overall survival (OS) rates were 39.5% and 60.4%, respectively. The role of upfront ASCT was evaluated in patients who were considered transplant-eligible (n=59). ASCT was performed as an upfront consolidative treatment in 32 (54.2%) of these patients. There were no significant differences in PFS and OS between the ASCT and non-ASCT groups for all patients (n=59) and for patients with PTCL-NOS (n=26). However, in patients with AITL, the ASCT group was associated with significantly better PFS than the non-ASCT group, although there was no significant difference in OS.
Conclusion The current study demonstrated that the survival outcomes with the current treatment options remain poor for patients with PTCL-NOS. Upfront ASCT may provide a survival benefit for patients with AITL, but not PTCL-NOS.
Citations
Citations to this article as recorded by
Successful Treatment, with Chemotherapy and Intravenous Administration of Ascorbic Acid, of a Patient with Peripheral T-Cell Lymphoma, Not Otherwise Specified Chiaki Tokoro, Atsushi Tashiro, Kenji Ina, Yoshiteru Tanaka, Hiroyuki Kobayakawa, Takashi Yoshida, Satoshi Kayukawa Journal of Cancer Research Updates.2024; 13: 1. CrossRef
Role of upfront autologous transplant for peripheral T-cell lymphoma patients achieving a complete remission with first-line therapy: a systematic review and meta-analysis L. Girard, Y. J. Koh, L. P. Koh, Y. L. Chee, H. L. Chan, J. Lee, S. de Mel, L. M. Poon, M. Samuel Bone Marrow Transplantation.2024; 59(6): 838. CrossRef
Angioimmunoblastic T-cell lymphoma and correlated neoplasms with T-cell follicular helper phenotype: from molecular mechanisms to therapeutic advances Luís Alberto de Pádua Covas Lage, Hebert Fabricio Culler, Cadiele Oliana Reichert, Sheila Aparecida Coelho da Siqueira, Juliana Pereira Frontiers in Oncology.2023;[Epub] CrossRef
Advances in the pathogenesis and therapeutic strategies of angioimmunoblastic T-cell lymphoma Qingyang Zhang, Le Yin, Qinqiao Lai, Yan Zhao, Hongling Peng Clinical and Experimental Medicine.2023; 23(8): 4219. CrossRef
Purpose The incidence of early-onset colorectal cancer (CRC) and associated mortality have been increasing. However, the potential benefits of CRC screening are largely unknown in young individuals. We aimed to evaluate the effect of CRC screening with colonoscopy on all-cause and CRC mortality among young (aged < 45 years) and older (aged ≥ 45 years) individuals.
Materials and Methods This cohort study included 528,046 Korean adults free of cancer at baseline who underwent a comprehensive health examination. The colonoscopic screening group was defined as those who reported undergoing colonoscopy for CRC screening. Mortality follow-up until December 31, 2019 was ascertained based on nationwide death certificate data from the Korea National Statistical Office.
Results Colonoscopic screening was associated with a lower risk of all-cause mortality in both young and older individuals. Multivariable-adjusted time-dependent hazard ratios (95% confidence intervals) for all-cause mortality comparing ever- to never-screening were 0.86 (0.75-0.99) for young individuals and 0.71 (0.65-0.78) for older individuals. Colonoscopic screenings were also associated with a reduced risk of CRC mortality without significant interaction by age, although this association was significant only among participants aged ≥ 45 years, with corresponding time-dependent hazard ratios of 0.47 (0.15-1.44) for young individuals and 0.52 (0.31-0.87) for those aged ≥ 45 years.
Conclusion Colonoscopic CRC screening decreased all-cause mortality among both young and older individuals, while significantly decreased CRC mortality was observed only in those aged ≥ 45 years. Screening initiation at an earlier age warrants more rigorous confirmatory studies.
Citations
Citations to this article as recorded by
Effect of screening mammography on the risk of breast cancer deaths and of all-cause deaths: a systematic review with meta-analysis of cohort studies Philippe Autier, Karsten Juhl Jørgensen, Michel Smans, Henrik Støvring Journal of Clinical Epidemiology.2024; 172: 111426. CrossRef
Identifying Gaps in Early-Onset Colorectal Cancer Prevention, Screening, and Treatment in the Philippines Luis Miguel B. Co, Robyn Gayle K. Dychiao, Michael Paolo R. Capistrano, Manolito T. Tayag, Erika P. Ong, Frances Dominique V. Ho, Michelle Ann B. Eala, Henri Cartier Co, Edward Christopher Dee, Marie Dione P. Sacdalan, Dennis L. Sacdalan Annals of Surgical Oncology.2024; 31(12): 7685. CrossRef
Association between colonoscopy and colorectal cancer occurrence and mortality in the older population: a population-based cohort study Ji Young Lee, Jae Myung Cha, Jin Young Yoon, Min Seob Kwak, Hun Hee Lee Endoscopy.2024;[Epub] CrossRef
Rising incidence and impact of early‐onset colorectal cancer in the Asia‐Pacific with higher mortality in females from Southeast Asia: a global burden analysis from 2010 to 2019 Pojsakorn Danpanichkul, Pinyada Moolkaew, Yatawee Kanjanakot, Natchaya Polpichai, Aunchalee Jaroenlapnopparat, Donghee Kim, Frank J. Lukens, Wahid Wassef, Michael B. Fallon, Vincent L. Chen, Rashid Lui, Karn Wijarnpreecha Journal of Gastroenterology and Hepatology.2023; 38(12): 2053. CrossRef
Jun Ho Yi, Seong Hyun Jeong, Seok Jin Kim, Dok Hyun Yoon, Hye Jin Kang, Youngil Koh, Jin Seok Kim, Won-Sik Lee, Deok-Hwan Yang, Young Rok Do, Min Kyoung Kim, Kwai Han Yoo, Yoon Seok Choi, Whan Jung Yun, Yong Park, Jae-Cheol Jo, Hyeon-Seok Eom, Jae-Yong Kwak, Ho-Jin Shin, Byeong Bae Park, Seong Yoon Yi, Ji-Hyun Kwon, Sung Yong Oh, Hyo Jung Kim, Byeong Seok Sohn, Jong Ho Won, Dae-Sik Hong, Ho-Sup Lee, Gyeong-Won Lee, Cheolwon Suh, Won Seog Kim
Cancer Res Treat. 2023;55(1):325-333. Published online April 22, 2022
Purpose Diffuse large B-cell lymphoma (DLBCL) is the most common hematologic malignancy worldwide. Although substantial improvement has been achieved by the frontline rituximab-based chemoimmunotherapy, up to 40%-50% of patients will eventually have relapsed or refractory disease, whose prognosis is extremely dismal.
Materials and Methods We have carried out two prospective cohort studies that include over 1,500 DLBCL patients treated with rituximab plus CHOP (#NCT01202448 and #NCT02474550). In the current report, we describe the outcomes of refractory DLBCL patients. Patients were defined to have refractory DLBCL if they met one of the followings, not achieving at least partial response after 4 or more cycles of R-CHOP; not achieving at least partial response after 2 or more cycles of salvage therapy; progressive disease within 12 months after autologous stem cell transplantation.
Results Among 1,581 patients, a total of 260 patients met the criteria for the refractory disease after a median time to progression of 9.1 months. The objective response rate of salvage treatment was 26.4%, and the complete response rate was 9.6%. The median overall survival (OS) was 7.5 months (95% confidence interval, 6.4 to 8.6), and the 2-year survival rate was 22.1%±2.8%. The median OS for each refractory category was not significantly different (p=0.529).
Conclusion In line with the previous studies, the outcomes of refractory DLBCL patients were extremely poor, which necessitates novel approaches for this population.
Citations
Citations to this article as recorded by
Recent advances in cellular immunotherapy for lymphoid malignancies Haerim Chung, Hyunsoo Cho Blood Research.2023; 58(4): 166. CrossRef
Sphingosine 1-phosphate receptor, a new therapeutic direction in different diseases Hongyu Chen, Junmin Wang, Caiyun Zhang, Peilun Ding, Shuxia Tian, Junming Chen, Guang Ji, Tao Wu Biomedicine & Pharmacotherapy.2022; 153: 113341. CrossRef
Sora Kang, Hyungwoo Cho, Shin Kim, Kyoungmin Lee, Eun Hee Kang, Jung Sun Park, Yoon Sei Lee, Chan-Sik Park, Heounjeong Go, Jooryung Huh, Jin Sook Ryu, Sang-Wook Lee, Seok Jin Kim, Won Seog Kim, Sang Eun Yoon, Young Hyeh Ko, Cheolwon Suh
Cancer Res Treat. 2023;55(1):314-324. Published online March 31, 2022
Purpose Prognostic Index for Natural Killer Lymphoma (PINK) is the most widely accepted prognostic model for patients withextranodal natural killer/T-cell lymphoma (ENKTL) treated with non-anthracycline–based therapy. We aimed to evaluate the prognostic implications of serum β-2 microglobulin (β2M) in the context of PINK and proposed a new prognostic model.
Materials and Methods A total of 138 patients who were newly diagnosed with ENKTL and treated with non-anthracycline-based chemotherapy were identified. The cut-off value of high serum β2M was calculated by maximal-chi square methods (4.1 mg/L). A new prognostic model incorporating serum β2M into PINK was proposed and validated in an independent validation cohort (n=88).
Results The patients’ median age was 53.5 years (range, 19 to 80 years). Patients with high serum β2M levels had significantly worse overall survival (OS) and progression-free survival (PFS). In multivariate analysis, high serum β2M was an independent adverse prognostic factor for OS. A new PINK-B (Prognostic Index for Natural Killer Lymphoma-serum β-2 microglobulin) model stratifiedpatients into three groups with distinct OS and PFS in the training cohort (3-year OS, 84.1% [95% confidence interval, 75.1 to 94.2], 46.8% [36.1 to 60.8] and 17.6% [6.3 to 49.2] for the low-, intermediate, and high-risk groups, respectively; 3-year PFS, 70.6% [59.4 to 83.8], 35.9% [25.9 to 49.8], and 7.35% [1.1 to 46.7] for the low-, intermediate-, and high-risk groups, respectively). The PINK-B model was further validated in an independent cohort.
Conclusion Serum β2M is an independent prognostic factor for ENKTL patients. The new serum β2M-based prognostic model may be useful for identifying ultra-high-risk patients, and it can easily be adopted into daily clinical practice.
Citations
Citations to this article as recorded by
Elevated serum IL-6 and total IgEAb are associated with poor survival in natural killer/T-cell lymphoma Yun Hui, Yingjun Gao, Jiawei Li, Qingtao Kong, Yuanyuan Duan, Haibo Liu, Fang Liu, Hong Sang Annals of Hematology.2024; 103(4): 1285. CrossRef
Prognostic Impact of Serum β2-Microglobulin Levels in Hodgkin Lymphoma Treated with ABVD or Equivalent Regimens: A Comprehensive Analysis of 915 Patients Theodoros P. Vassilakopoulos, Maria Arapaki, Panagiotis T. Diamantopoulos, Athanasios Liaskas, Fotios Panitsas, Marina P. Siakantaris, Maria Dimou, Styliani I. Kokoris, Sotirios Sachanas, Marina Belia, Chrysovalantou Chatzidimitriou, Elianna A. Konstantin Cancers.2024; 16(2): 238. CrossRef
Prognostic Value of18F-FDG PET/CT Radiomics in Extranodal Nasal-Type NK/T Cell Lymphoma Yu Luo, Zhun Huang, Zihan Gao, Bingbing Wang, Yanwei Zhang, Yan Bai, Qingxia Wu, Meiyun Wang Korean Journal of Radiology.2024; 25(2): 189. CrossRef
A novel prognostic index for extranodal natural killer/T-cell lymphoma in the era of pegaspargase/L-asparaginase Ziyuan Shen, Xudong Zhang, Yujie Li, Xicheng Chen, Xing Xing, Hao Zhang, Jingjing Ye, Ling Wang, Tao Jia, Taigang Zhu, Yuqing Miao, Chunling Wang, Hui Liu, Liang Wang, Wei Sang Future Oncology.2024; 20(28): 2071. CrossRef
Mee Joo Kang, Young-Joo Won, Jae Jun Lee, Kyu-Won Jung, Hye-Jin Kim, Hyun-Joo Kong, Jeong-Soo Im, Hong Gwan Seo, The Community of Population-Based Regional Cancer Registries
Cancer Res Treat. 2022;54(2):330-344. Published online March 16, 2022
Purpose
The current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in 2019.
Materials and Methods
Incidence, survival, and prevalence rates of cancer were calculated using the Korea National Cancer Incidence Database, from 1999 to 2019, with survival follow-up until December 31, 2020. Deaths from cancer were assessed using causes-of-death data obtained from Statistics Korea.
Results
In 2019, newly diagnosed cancer cases and deaths from cancer were reported as 254,718 (ASR, 275.4 per 100,000) and 81,203 (ASR, 72.2 per 100,000), respectively. For the first time, lung cancer (n=29,960) became the most frequent cancer in Korea, excluding thyroid cancer. The overall cancer incidence rates increased by 3.3% annually from 1999 to 2012, and decreased by 5.3% annually from 2012 to 2015, thereafter, followed by nonsignificant changes. The incidence of thyroid cancer increased again from 2016 (annual percentage change, 6.2%). Cancer mortality rates have been decreasing since 2002, with more rapid decline in recent years (annual decrease of 2.7% from 2002 to 2013; 3.3% from 2013 to 2019). The 5-year relative survival between 2015 and 2019 was 70.7%, which contributed to prevalent cases reaching over 2 million in 2019.
Conclusion
Cancer survival rates have improved over the past decades, but the number of newly diagnosed cancers is still increasing, with some cancers showing only marginal improvement in survival outcomes. As the number of cancer survivors increases, a comprehensive cancer control strategy should be implemented in line with the changing aspects of cancer statistics.
Citations
Citations to this article as recorded by
Factors Associated With Quality of Life Among Posttreatment Cancer Survivors in Korea Soo Hyun Kim, Yu Hyeon Choe, Jingyeong Choi, Ji Young Park, Eun Yi Cancer Nursing.2025; 48(1): E47. CrossRef
Survival feature and trend of female breast cancer: A comprehensive review of survival analysis from cancer registration data Dan-Dan Tang, Zhuo-Jun Ye, Wan-Wan Liu, Jing Wu, Jing-Yu Tan, Yan Zhang, Qun Xu, Yong-Bing Xiang The Breast.2025; 79: 103862. CrossRef
Survey of the Actual Practices Used for Endoscopic Removal of Colon Polyps in Korea: A Comparison with the Current Guidelines Jeongseok Kim, Tae-Geun Gweon, Min Seob Kwak, Su Young Kim, Seong Jung Kim, Hyun Gun Kim, Sung Noh Hong, Eun Sun Kim, Chang Mo Moon, Dae Seong Myung, Dong-Hoon Baek, Shin Ju Oh, Hyun Jung Lee, Ji Young Lee, Yunho Jung, Jaeyoung Chun, Dong-Hoon Yang, Eun R Gut and Liver.2025; 19(1): 77. CrossRef
Epidemiology and survival analysis according to the histologic subtype of pancreatic cancer: a population-based cohort study Hyeong Min Park, Mee Joo Kang, Sang-Jae Park, Kyu-Won Jung, Sung-Sik Han Annals of Surgical Treatment and Research.2025; 108(1): 20. CrossRef
Cancer incidence and the influence of immunosuppressive agents in Korean patients with systemic lupus erythematosus: a retrospective cohort study Soo-Kyung Cho, Jung-Yong Han, Yena Jeon, Seung-Hun You, Sun-Young Jung, Eun Jin Jang, Yoon-Kyoung Sung Arthritis Research & Therapy.2025;[Epub] CrossRef
Recent 5‑year trends in biliary tract cancer survival rates: An analytical big data survey Ji Yoon Lee, Ju Won Kim Medicine International.2025;[Epub] CrossRef
Effects of Anticancer Therapy on Osteoporosis in Breast Cancer Patients: A Nationwide Study Using Data from the National Health Insurance Service-National Health Information Database Minji Kwon, Bo-Hyung Kim, Sun Young Min, Sumin Chae Journal of Clinical Medicine.2025; 14(3): 732. CrossRef
Risk of Cancers According to the Use of Biological Agents in Patients With Radiographic Axial Spondyloarthritis Oh Chan Kwon, Hye Sun Lee, Juyeon Yang, Min-Chan Park JCR: Journal of Clinical Rheumatology.2025;[Epub] CrossRef
Risk of second primary malignancies among survivors of cutaneous melanoma: A nationwide population-based study in the Republic of Korea Joon Min Jung, Do Hyung Kim, Ye-Jee Kim, Ik Jun Moon, Woo Jin Lee, Sung Eun Chang, Mi Woo Lee, Chong Hyun Won Scientific Reports.2025;[Epub] CrossRef
Adherence of PARP inhibitor for frontline maintenance therapy in primary epithelial ovarian cancer: a cross-sectional survey Ji Hyun Kim, Yumi Lee, Da-Young Kim, Sinae Kim, Sang-Soo Seo, Sokbom Kang, Sang-Yoon Park, Myong Cheol Lim Journal of Gynecologic Oncology.2024;[Epub] CrossRef
The association of diet-dependent acid load with colorectal cancer risk: a case–control study in Korea Tao Thi Tran, Madhawa Gunathilake, Jeonghee Lee, Jae Hwan Oh, Hee Jin Chang, Dae Kyung Sohn, Aesun Shin, Jeongseon Kim British Journal of Nutrition.2024; 131(2): 333. CrossRef
Quantitative assessment of breast volume changes after whole-breast irradiation for breast cancer using breast auto-segmentation Tae Hoon Lee, Sang Hee Ahn, Kwangzoo Chung, Won Park, Won Kyung Cho, Nalee Kim, Tae Gyu Kim, Haeyoung Kim Breast Cancer Research and Treatment.2024; 203(2): 205. CrossRef
Regularity of cervical cancer screening in Korea: analysis using national public data for 12 years Jong-Yeup Kim, Jeeyoung Hong, Juhee Yoon, Jinsol Park, Tae-Hyun Kim Journal of Gynecologic Oncology.2024;[Epub] CrossRef
Dietary Isoflavone Intake and Breast Cancer Prognosis: A Prospective Analysis and Meta-Analysis Sihan Song, Jong-Ho Cheun, Hyeong-Gon Moon, Dong-Young Noh, So-Youn Jung, Eun Sook Lee, Zisun Kim, Hyun Jo Youn, Jihyoung Cho, Young Bum Yoo, Shinyoung Jun, Hyojee Joung, Jung Eun Lee Nutrition and Cancer.2024; 76(1): 42. CrossRef
Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer (KCSG-BR15-17): A randomized, open-label, multicenter, phase II trial Dae-Won Lee, Kyung Hae Jung, Kyung-Hun Lee, Yeon Hee Park, Keun Seok Lee, Joohyuk Sohn, Hee Kyung Ahn, Jae Ho Jeong, Su-Jin Koh, Jee Hyun Kim, Han Jo Kim, Kyoung Eun Lee, Hee-Jun Kim, Yae-Won Yang, Kyong Hwa Park, Jieun Lee, Hye Sung Won, Tae-Yong Kim, Se European Journal of Cancer.2024; 197: 113456. CrossRef
Maintaining Healthy Fasting Blood Glucose Levels Is Important for Korean Cancer Survivors Jaehoon Chung CardioMetabolic Syndrome Journal.2024; 4(1): 20. CrossRef
Subsite‐specific trends in mid‐ and long‐term survival for head and neck cancer patients in Japan: A population‐based study Hiroshi Tsuge, Daisuke Kawakita, Yukari Taniyama, Isao Oze, Yuriko N. Koyanagi, Megumi Hori, Kayo Nakata, Hiromi Sugiyama, Isao Miyashiro, Izumi Oki, Yoshikazu Nishino, Kota Katanoda, Yuri Ito, Akiko Shibata, Tomohiro Matsuda, Shinichi Iwasaki, Keitaro Ma Cancer Science.2024; 115(2): 623. CrossRef
Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset Ki Hyeong Lee, Byoung Chul Cho, Myung-Ju Ahn, Yun-Gyoo Lee, Youngjoo Lee, Jong-Seok Lee, Joo-Hang Kim, Young Joo Min, Gyeong-Won Lee, Sung Sook Lee, Kyung-Hee Lee, Yoon Ho Ko, Byoung Yong Shim, Sang-We Kim, Sang Won Shin, Jin-Hyuk Choi, Dong-Wan Kim, Eun Cancer Research and Treatment.2024; 56(1): 48. CrossRef
Conditional Relative Survival of Exocrine Pancreatic Cancer: A Population-Based Study Mee Joo Kang, Johyun Ha, Hyeong Min Park, Sang-Jae Park, Kyu-Won Jung, Sung-Sik Han Annals of Surgical Oncology.2024; 31(2): 1178. CrossRef
Trends in the incidence and survival outcomes of endometrial cancer in Korea: a nationwide population-based cohort study Seung-Hyuk Shim, Jiwon Lim, Ji Hyun Kim, Yeon Jee Lee, Hyeong In Ha, Myong Cheol Lim, Young-Joo Won Journal of Gynecologic Oncology.2024;[Epub] CrossRef
Twenty-two-year incidence trend of urological cancers in the Republic of Korea: 1999–2020 Seunghyeon Cho, Won-Ju Park Investigative and Clinical Urology.2024; 65(1): 23. CrossRef
Efficacy of preoperative lymphoscintigraphy in predicting surgical outcomes of lymphaticovenous anastomosis in lower extremity lymphedema: Clinical correlations in gynecological cancer-related lymphedema Min Young Yoo, Kyong-Je Woo, Seo Young Kang, Byung Seok Moon, Bom Sahn Kim, Hai-Jeon Yoon, Andrea Giannini PLOS ONE.2024; 19(1): e0296466. CrossRef
Analysis of distress in patients undergoing radical prostatectomy: A multicenter prospective study Duk Yoon Kim, Jae Hyun Ryu, Tag Keun Yoo, Yun Beom Kim, Tae Young Jung, Woo Jin Ko, Eun Kyoung Yang Investigative and Clinical Urology.2024; 65(1): 40. CrossRef
Potential role of Fibrosis‐4 score in hepatocellular carcinoma screening: The Kangbuk Samsung Health Study Sujeong Shin, Won Sohn, Yoosoo Chang, Yoosun Cho, Min‐Jung Kwon, Sarah H. Wild, Christopher D. Byrne, Seungho Ryu Hepatology Research.2024; 54(6): 551. CrossRef
Comparison of the Prognosis of Upper-Third Gastric Cancer With That of Middle and Lower-Third Gastric Cancer Ji Yeon Park, Eun Ji Kim, Jae Yeong Yang, Ki Bum Park, Oh Kyoung Kwon Journal of Gastric Cancer.2024; 24(2): 159. CrossRef
Genomic and Transcriptomic Characterization of Gastric Cancer with Bone Metastasis Sujin Oh, Soo Kyung Nam, Keun-Wook Lee, Hye Seung Lee, Yujun Park, Yoonjin Kwak, Kyu Sang Lee, Ji-Won Kim, Jin Won Kim, Minsu Kang, Young Suk Park, Sang-Hoon Ahn, Yun-Suhk Suh, Do Joong Park, Hyung Ho Kim Cancer Research and Treatment.2024; 56(1): 219. CrossRef
Long-Term Outcomes of Colon Conduits in Surgery for Primary Esophageal Cancer: A Propensity Score-Matched Comparison to Gastric Conduits Jae Hoon Kim, Jae Kwang Yun, Chan Wook Kim, Hyeong Ryul Kim, Yong-Hee Kim Journal of Chest Surgery.2024; 57(1): 53. CrossRef
Injectable Mesocellular Foam Silica Microparticles with a Dual Role of Cell‐Recruiting Scaffolds and Intracellular Delivery Vehicles for Enhanced Cancer Vaccine Jihye Im, Youngjin Choi, Thanh Loc Nguyen, Min Kyung Kim, Jaeyun Kim Advanced Functional Materials.2024;[Epub] CrossRef
Pretreatment Interstitial Lung Abnormalities Detected on Abdominal Computed Tomography Scans in Prostate Cancer Patients Hyun Jin Kim, Won Gi Jeong, Jeong Yeop Lee, Hyo-Jae Lee, Byung Chan Lee, Hyo Soon Lim, Yun-Hyeon Kim Journal of Computer Assisted Tomography.2024; 48(3): 406. CrossRef
Perinatal and childhood outcomes of children born to female cancer survivors in South Korea Ju Hyun Jin, Tae Mi Youk, Jisun Yun, Ja Yoon Heo Scientific Reports.2024;[Epub] CrossRef
Changes in the Epidemiologic Pattern of Primary CNS Tumors in Response to the Aging Population: An Updated Nationwide Cancer Registry Data in the Republic of Korea Yoon Hwan Byun, Johyun Ha, Ho Kang, Chul-Kee Park, Kyu-Won Jung, Heon Yoo JCO Global Oncology.2024;[Epub] CrossRef
Efficacy and Toxicity of Palliative Chemotherapy in Elderly Patients With Advanced Pancreatic Cancer Han Taek Jeong, Ho Gak Kim, Jimin Han Pancreas.2024; 53(3): e268. CrossRef
Tubulointerstitial nephritis antigen-like 1 from cancer-associated fibroblasts contribute to the progression of diffuse-type gastric cancers through the interaction with integrin β1 Dagyeong Lee, In-Hye Ham, Hye Jeong Oh, Dong Min Lee, Jung Hwan Yoon, Sang-Yong Son, Tae-Min Kim, Jae-Young Kim, Sang-Uk Han, Hoon Hur Journal of Translational Medicine.2024;[Epub] CrossRef
The Association of Low-Carbohydrate Diet and HECTD4 rs11066280 Polymorphism with Risk of Colorectal Cancer: A Case-Control Study in Korea Tao Thi Tran, Madhawa Gunathilake, Jeonghee Lee, Jae Hwan Oh, Hee Jin Chang, Dae Kyung Sohn, Aesun Shin, Jeongseon Kim Current Developments in Nutrition.2024; 8(3): 102127. CrossRef
Assessing visibility and bone changes of spinal metastases in CT scans: a comprehensive analysis across diverse cancer types Jung Oh Lee, Dong Hyun Kim, Hee-Dong Chae, Eugene Lee, Ji Hee Kang, Ji Hyun Lee, Hyo Jin Kim, Jiwoon Seo, Jee Won Chai Skeletal Radiology.2024; 53(8): 1553. CrossRef
Living experiences of older patients with cancer amid the COVID-19 pandemic: A phenomenological study Yong Hwan Hyeon, Kyoung Ja Moon Journal of Korean Gerontological Nursing.2024; 26(1): 54. CrossRef
Evaluation of clinical usefulness of HPV-16 and HPV-18 genotyping for cervical cancer screening Eun Hye Cho, Min-Seung Park, Hee-Yeon Woo, Hyosoon Park, Min-Jung Kwon Journal of Gynecologic Oncology.2024;[Epub] CrossRef
Assessment and validation of glottic motion using cone-beam CT and real-time cine MRI Seok-Joo Chun, Jaeman Son, Seonghee Kang, Chang Heon Choi, Jung-in Kim, Young-Il Kim, Joo Ho Lee, Jin Ho Kim, Hong-Gyun Wu Strahlentherapie und Onkologie.2024; 200(5): 418. CrossRef
Risk of Subsequent Primary Cancers Among Adult-Onset 5-Year Cancer Survivors in South Korea: Retrospective Cohort Study Yoon Young Choi, Myeongjee Lee, Eun Hwa Kim, Jae Eun Lee, Inkyung Jung, Jae-Ho Cheong JMIR Public Health and Surveillance.2024; 10: e48380. CrossRef
Glycemic traits and colorectal cancer survival in a cohort of South Korean patients: A Mendelian randomization analysis So Yon Jun, Sooyoung Cho, Min Jung Kim, Ji Won Park, Seung‐Bum Ryoo, Seung Yong Jeong, Kyu Joo Park, Aesun Shin Cancer Medicine.2024;[Epub] CrossRef
Sex-specific associations of empirically derived dietary patterns with colorectal cancer risk in a Korean population: a case‒control study Minji Kim, Madhawa Gunathilake, Jeonghee Lee, Jae Hwan Oh, Hee Jin Chang, Dae Kyung Sohn, Aesun Shin, Jeongseon Kim Scientific Reports.2024;[Epub] CrossRef
Risk prediction model for gastric cancer within 5 years in healthy Korean adults Hyungseok Oh, Sunwoo Cho, Jung Ah Lee, Seungho Ryu, Yoosoo Chang Gastric Cancer.2024; 27(4): 675. CrossRef
Contents analysis of thyroid cancer-related information uploaded to YouTube by physicians in Korea: endorsing thyroid cancer screening, potentially leading to overdiagnosis EunKyo Kang, HyoRim Ju, Soojeong Kim, Juyoung Choi BMC Public Health.2024;[Epub] CrossRef
Implication of Pre- and Post-radiotherapy ctDNA Dynamics in Patients with Residual Triple-Negative Breast Cancer at Surgery after Neoadjuvant Chemotherapy: Findings from a Prospective Observational Study Tae Hoon Lee, Haeyoung Kim, Yeon Jeong Kim, Woong-Yang Park, Won Park, Won Kyung Cho, Nalee Kim Cancer Research and Treatment.2024; 56(2): 531. CrossRef
The interaction effect of dietary selenium intake and the IL10 rs1800871 polymorphism on the risk of colorectal cancer: a case–control study in Korea Tao Thi Tran, Madhawa Gunathilake, Jeonghee Lee, Jae Hwan Oh, Hee Jin Chang, Dae Kyung Sohn, Aesun Shin, Jeongseon Kim British Journal of Nutrition.2024; 131(12): 2039. CrossRef
Monte Carlo Simulation-Based Mammographic Anti-Scatter Grids to Evaluate Performance of Digital Mammography Detector Yeji Kim, Hyejin Jo, Yongsu Yoon Journal of Radiological Science and Technology.2024; 47(1): 1. CrossRef
Secondary hematological malignancies in patients with sarcoma: A single‑center retrospective study Yoon Jang, Hong Jeong, Chang-Bae Kong, Won Song, Wan Cho, Dae Jeon, Heyjin Kim, Sung Yang, Im Na, Hyo-Rak Lee, Hye Kang Oncology Letters.2024;[Epub] CrossRef
Association between non-healing precancerous oral lesions and ulcers with tobacco smoking: A population-based study Olawale Olatunbosun Adamson, Olufemi Erinoso, Remilekun Oluwakuyide, Abiodun Amao, Olajumoke Effiom, Olalekan Micah Gbotolorun Oral Oncology Reports.2024; 10: 100428. CrossRef
Comparative Study of Diabetes Knowledge, Attitudes, Family Support, Self-efficacy, and Self-management Behaviors Between Cancer Survivors With Diabetes and Diabetes Patients Without Cancer Eun Jeong Ko, Su Jung Lee Cancer Nursing.2024;[Epub] CrossRef
Optimal Dietary Intake of Riboflavin Associated with Lower Risk of Cervical Cancer in Korea: Korean National Health and Nutrition Examination Survey 2010–2021 Seon-Mi Lee, Aeran Seol, Hyun-Woong Cho, Kyung-Jin Min, Sanghoon Lee, Jin-Hwa Hong, Jae-Yun Song, Jae-Kwan Lee, Nak-Woo Lee Life.2024; 14(4): 529. CrossRef
Sex differences of the association between handgrip strength and health-related quality of life among patients with cancer Jihye Kim, Yujin Kim, Jae Won Oh, San Lee Scientific Reports.2024;[Epub] CrossRef
Elucidating immunological characteristics of the adenoma-carcinoma sequence in colorectal cancer patients in South Korea using a bioinformatics approach Jaeseung Song, Daeun Kim, Junghyun Jung, Eunyoung Choi, Yubin Lee, Yeonbin Jeong, Byungjo Lee, Sora Lee, Yujeong Shim, Youngtae Won, Hyeki Cho, Dong Kee Jang, Hyoun Woo Kang, Jong Wha J. Joo, Wonhee Jang Scientific Reports.2024;[Epub] CrossRef
No Change in Complications Following Thyroidectomy Despite Increase in Thyroid Cancer Surgeries: A Meta-Regression Analysis Jun Sung Lee, Jin Seok Lee, Hyeok Jun Yun, Seok-Mo Kim, Hojin Chang, Yong Sang Lee, Juyeon Yang, Hye Sun Lee, Hang-Seok Chang Yonsei Medical Journal.2024; 65(6): 348. CrossRef
Clinical significance of the advanced lung cancer inflammation index in patients with limited-stage small cell lung cancer treated with chemoradiotherapy Bo Mi Seo, Jiin Choi, Boksoon Chang, Bo-Guen Kim, Tai Sun Park, Hyun Lee, Ji-Yong Moon, Sang-Heon Kim, Tae-Hyung Kim, Seung-Jin Yoo, Hae Jin Park, Ho Joo Yoon, Jang Won Sohn, Seung Hyeun Lee, Dong Won Park Scientific Reports.2024;[Epub] CrossRef
Comparative analysis of genetic testing utilization rates among people with and without disabilities in South Korea from 2016 to 2019, focusing on malignant neoplasms: A national population‐based study Gwanwook Bang, Minji Park, Jeong‐yeon Seon, So‐Youn Park Cancer Medicine.2024;[Epub] CrossRef
Thyroid Cancer Incidence Among Korean Individuals: A Comparison of South Korea and the United States Dohun Kim, Guan Li, Peter K. Moon, Yifei Ma, Soohyun Sim, Sung Y. Park, Minkyung Oh, Uchechukwu C. Megwalu The Laryngoscope.2024; 134(9): 4156. CrossRef
Risk Factors and Mortality Among Women With Interval Breast Cancer vs Screen-Detected Breast Cancer Huiyeon Song, Thi Xuan Mai Tran, Soyeoun Kim, Boyoung Park JAMA Network Open.2024; 7(5): e2411927. CrossRef
Survival of Patients with Primary Brain Tumor: A Data Analysis of 10 Years Shristy Verma, Rishabha Malviya, Prerna Uniyal Current Pharmaceutical Design.2024; 30(15): 1129. CrossRef
Neoadjuvant Cisplatin-Based Chemotherapy Followed by Selective Bladder Preservation Chemoradiotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder: Post Hoc Analysis of Two Prospective Studies Sung Wook Cho, Sung Hee Lim, Ghee Young Kwon, Chan Kyo Kim, Won Park, Hongryull Pyo, Jae Hoon Chung, Wan Song, Hyun Hwan Sung, Byong Chang Jeong, Se Hoon Park Cancer Research and Treatment.2024; 56(3): 893. CrossRef
The risk for subsequent primary lung cancer after cervical carcinoma: A quantitative analysis based on 864,627 cases Sheng Gong, Gang Li, Dan Li, Yu Liu, Banggui Wu, Yan Wang PLOS ONE.2024; 19(6): e0305670. CrossRef
Analysis of Aeromedical Consultation Related to Malignant Tumor of Korean Military Flight Crews Du Hyun Song The Korean Journal of Aerospace and Environmental Medicine.2024; 34(2): 40. CrossRef
Seasonal influences on the efficacy of anti–programmed cell death (ligand) 1 inhibitors in lung cancer Hyunsoon Cho, Hoejun Kwon, Se Hyun Kim, Hyung‐Min Ahn, Beom K. Choi, Geon Kook Lee, Seog‐Yun Park, Hyun‐ju Lim, Jung‐Ah Hwang, Jiyeon Lim, Ji‐Youn Han, Youngjoo Lee Cancer.2024;[Epub] CrossRef
Surveillance for Distant Metastasis in Breast Cancer Patients Who Underwent Contemporary Management: A Report from the Korean Breast Cancer Society Survivor Research Group Jong-Ho Cheun, Sooyeon Chung, Jai Hong Han, Young-Won Lee, Ji-Jung Jung, Jung Whan Chun, Eun-Gyeong Lee, Jun Won Min, Zisun Kim, Jihyoun Lee, So-Youn Jung, Yoo Seok Kim, Jong Han Yu, Eun-Kyu Kim, Jong-Won Lee, Ki-Tae Hwang, Ku Sang Kim, Hyun Jo Youn, Hyeo Annals of Surgical Oncology.2024; 31(10): 6774. CrossRef
Disparities in the diagnosis and treatment of colorectal cancer among patients with disabilities Ki Bae Kim, Dong Wook Shin, Kyoung Eun Yeob, So Young Kim, Joung-Ho Han, Seon Mee Park, Jong Heon Park, Jong Hyock Park World Journal of Gastrointestinal Oncology.2024; 16(7): 2925. CrossRef
Optimization and Stabilization of Automated Synthesis Systems for Reduced 68Ga-PSMA-11 Synthesis Time Ji hoon KANG, Sang Min SHIN, Young Si PARK, Hea Ji KIM, Hwa Youn JANG Korean Journal of Clinical Laboratory Science.2024; 56(2): 147. CrossRef
Clinical impact of pancreatic invasion in T1‐stage distal bile duct cancer and prognostic factors associated with long‐term survival: A multicenter study Ye Won Jeon, Chang Moo Kang, Yoo‐Seok Yoon, Wooil Kwon, Sung‐Sik Han, Yejong Park, Bong Jun Kwak, Woohyung Lee, Ki Byung Song, Jae Hoon Lee, Song Cheol Kim, Sang Hyun Shin, Dae Wook Hwang Journal of Hepato-Biliary-Pancreatic Sciences.2024; 31(9): 658. CrossRef
Comparison of the treatment outcomes of different neoadjuvant chemoradiotherapy regimens for resectable locally advanced esophageal cancer Hyunki Park, Kyungmi Yang, Jae Myoung Noh, Young Mog Shim, Hong Kwan Kim, Yong Soo Choi, Jong Ho Cho, Jong-Mu Sun, Hyun Ae Jung, Sehhoon Park, Hana Park, Dongryul Oh Journal of Gastrointestinal Surgery.2024; 28(11): 1745. CrossRef
Korean National Burden of Disease: The Importance of Diabetes Management Chung-Nyun Kim, Yoon-Sun Jung, Young-Eun Kim, Minsu Ock, Seok-Jun Yoon Diabetes & Metabolism Journal.2024; 48(4): 518. CrossRef
Trends in multiple myeloma incidence, prevalence, mortality, and survival rate in South Korea: a nationwide population-based study Boyoung Park, Junghyun Yoon, YooSun Lee, YoungJu Park, Hyeon-Seok Eom Annals of Hematology.2024; 103(10): 4111. CrossRef
Efficacy and safety of laser ablation and microwave ablation to treat papillary thyroid microcarcinoma: A retrospective study Yuqing Huang, Xinyu Zhao, Yu Yang, Lanyan Qiu, Junfeng Zhao, Linxue Qian, Xianquan Shi American Journal of Otolaryngology.2024; 45(6): 104496. CrossRef
Insurance Types and All-Cause Mortality in Korean Cancer Patients: A Nationwide Population-Based Cohort Study Jinyoung Shin, Yoon-Jong Bae, Hee-Taik Kang Journal of Personalized Medicine.2024; 14(8): 861. CrossRef
Disparities in Overall Survival Rates for Cancers across Income Levels in the Republic of Korea Su-Min Jeong, Kyu-Won Jung, Juwon Park, Hyeon Ji Lee, Dong Wook Shin, Mina Suh Cancers.2024; 16(16): 2923. CrossRef
Interactions between vitamin B2, the MTRR rs1801394 and MTR rs1805087 genetic polymorphisms, and colorectal cancer risk in a Korean population Madhawa Gunathilake, Minji Kim, Jeonghee Lee, Jae Hwan Oh, Hee Jin Chang, Dae Kyung Sohn, Aesun Shin, Jeongseon Kim Epidemiology and Health.2024; 46: e2024037. CrossRef
Risk factors and incidence of oral tumors: Findings from a longitudinal population‐based study Young‐Taek Kim, Min‐Jin Kang, Bo‐Ah Lee, Sang‐Hoon Kang, Reuben H. Kim Oral Diseases.2024;[Epub] CrossRef
Clinical outcomes and safety of external beam radiotherapy with extensive intrahepatic targets for advanced hepatocellular carcinoma: A single institutional clinical experience Sunmin Park, Chai Hong Rim, Won Sup Yoon Saudi Journal of Gastroenterology.2024; 30(6): 399. CrossRef
Is Chronic Ice Water Ingestion a Risk Factor for Gastric Cancer Development? An Evidence-Based Hypothesis Focusing on East Asian Populations Farzad Taghizadeh-Hesary Oncology and Therapy.2024; 12(4): 629. CrossRef
Real-world safety and effectiveness of lenvatinib in unresectable hepatocellular carcinoma in Korea: post-marketing study Wonseok Kang, Yoon Jun Kim, Seung Up Kim, Yeon Seok Seo, Jin-Wook Kim, Ji Hoon Kim, Soo Young Park, Yang-Hyun Baek, Kang Mo Kim, Hae Lim Lee, Ki Tae Yoon, Hyeyeong Kim, Jae Youn Cheong, Jae Seok Hwang, Ju Hyun Kim, Kwang Min Kim, Pil Soo Sung, Jieun Kim, Future Oncology.2024; 20(37): 2949. CrossRef
Thyroid cancer-specific mortality during 2005–2018 in Korea, aftermath of the overdiagnosis issue: a nationwide population-based cohort study Kyeong Jin Kim, Jimi Choi, Sue K. Park, Young Joo Park, Sin Gon Kim International Journal of Surgery.2024; 110(9): 5489. CrossRef
Post-Treatment Experiences of Reproductive Concerns Among Young Breast Cancer Survivors: A Descriptive Phenomenological Study Wenjing Xu, Xiangyu Liu, Cuicui Zhang, Lili Zhu, Yuxiu Zhao, Changju Liao Asian Nursing Research.2024; 18(4): 331. CrossRef
Regional Impact of the COVID-19 Pandemic on Cancer Screening Jongho Park, Yeaeun Kim, Jae-Hyun Park Asia Pacific Journal of Public Health.2024; 36(8): 760. CrossRef
Incidence and pattern of second primary cancer in patients diagnosed with primary cancer Jong Sung, Ae Ahn, Ho Park, Kyu Jang, Woo Moon, Ju-Hyung Lee, Kyoung Kim, Myoung Chung Oncology Letters.2024;[Epub] CrossRef
The effects of sarcopenic obesity on immediate postoperative outcomes after pancreatoduodenectomy: a retrospective cohort study Jae Hwan Jeong, Ji Su Kim, Seung-seob Kim, Seung Soo Hong, Ho Kyoung Hwang, Chang Moo Kang, Hyoung-Il Kim, Kyung Sik Kim, Sung Hyun Kim Annals of Surgical Treatment and Research.2024; 107(4): 203. CrossRef
Prognostic Significance of Bulky Nodal Disease in Anal Cancer Management: A Multi-institutional Study Seok-Joo Chun, Eunji Kim, Won Il Jang, Mi-Sook Kim, Hyun-Cheol Kang, Byoung Hyuck Kim, Eui Kyu Chie Cancer Research and Treatment.2024; 56(4): 1197. CrossRef
Lesson from COVID-19 outbreak; importance of standard precautions to febrile neutropenia prevention in patients with breast cancer who received adjuvant chemotherapy: a retrospective observational study Ji Eun Park, Jieun Yang, Sanghoon Han, Jeong Rae Yoo, Misun Kim, Donghyoun Lee, Jaemin Jo Annals of Surgical Treatment and Research.2024; 107(4): 195. CrossRef
Development and Feasibility Evaluation of Smart Cancer Care 2.0 Based on Patient-Reported Outcomes for Post-Discharge Management of Patients with Cancer Jin Ah Kwon, Songsoo Yang, Su-Jin Koh, Young Ju Noh, Dong Yoon Kang, Sol Bin Yang, Eun Ji Kwon, Jeong-Wook Seo, Jin sung Kim, Minsu Ock Cancer Research and Treatment.2024; 56(4): 1040. CrossRef
Re-evaluation of the role of endoscopic submucosal dissection in the treatment of early gastric cancer based on additional gastrectomy results Dong Won Im, Jae Hun Chung, Dae-Gon Ryu, Cheol Woong Choi, Su Jin Kim, Sun-Hwi Hwang, Si-Hak Lee Medicine.2024; 103(41): e40111. CrossRef
Transforming public health and economic outcomes by reducing risky behaviors: the potential for South Korea Joan E. Madia, Ji Yoon Baek, Aesun Shin Discover Social Science and Health.2024;[Epub] CrossRef
Prognostic value of the systemic immune-inflammation index in lung cancer patients receiving immune checkpoint inhibitors: A meta-analysis Yanhui Yang, Ji Li, Yi Wang, Lei Luo, Yi Yao, Xiaoyang Xie, Gayle E. Woloschak PLOS ONE.2024; 19(11): e0312605. CrossRef
Cohort Profile: The Registry-based Epidemiological Study of Cancer in Fire Unit and Emergency Officers (RESCUE) cohort Wonjeong Jeong, Yoon A Kim, Soo Yeon Song, Dong-Hee Koh, Hyoung-Ryoul Kim, Jae-Lim Cho, Changsoo Kim, Jae Kwan Jun International Journal of Epidemiology.2024;[Epub] CrossRef
The discrepancy of somatic BRCA1/2 pathogenic variants from two different platforms in epithelial ovarian, fallopian tube, and peritoneal cancer Ji Hyun Kim, Jun-Young Shin, Seog-Yun Park, Sang-Soo Seo, Sokbom Kang, Chong Woo Yoo, Sang-Yoon Park, Myong Cheol Lim Scientific Reports.2024;[Epub] CrossRef
Application of a Novel Multimodal-Based Deep Learning Model for the Prediction of Papillary Thyroid Carcinoma Recurrence Dong-Hwa Lee, Jee-Woo Choi, Geun-Hyeong Kim, Seung Park, Hyun Jeong Jeon International Journal of General Medicine.2024; Volume 17: 6585. CrossRef
F-18 FDG PET/CT Clinical Service Trends in Korea from 2018 to 2022: A National Surveillance Study Jaesun Yoon, Heejin Kim, Do Hyun Woo, Seung Yeop Chae, Ji Heui Lee, Inki Lee, Ilhan Lim, Byung Il Kim, Chang Woon Choi, Byung Hyung Byun Nuclear Medicine and Molecular Imaging.2024;[Epub] CrossRef
Mismatch repair, p53, and L1 cell adhesion molecule status influence the response to chemotherapy in advanced and recurrent endometrial cancer Jung Chul Kim, Byungsoo Ahn, Yong Jae Lee, Eun Ji Nam, Sang Wun Kim, Sunghoon Kim, Young Tae Kim, Eunhyang Park, Jung-Yun Lee BMC Cancer.2024;[Epub] CrossRef
Thyroid cancer survival and prognostic factors in Yantai, China (2012–2022): a population-based study Haiyun Liu, Shuxia Zhang, Xiaohui Liu, Qianqian Wang, Hongjie Zhang, Weihong Cui BMC Cancer.2024;[Epub] CrossRef
Dietary mercury intake, the IL23R rs10889677 polymorphism, and the risk of gastric cancer in a Korean population: a hospital-based case-control study Ji Hyun Kim, Madhawa Gunathilake, Jeonghee Lee, Il Ju Choi, Young-Il Kim, Jeongseon Kim Epidemiology and Health.2024; 46: e2024051. CrossRef
Current treatment patterns within 1 year after prostate cancer diagnosis in Korean patients over 75 years old: a retrospective multicenter study Dong Jin Park, Ho Won Kang, Se Yun Kwon, Young Jin Seo, Kyung Seop Lee, Byung Hoon Kim, Teak Jun Shin, Won Tae Kim, Yong-June Kim, Seok Joong Yun, Sang-Cheol Lee, Jae-Wook Chung, Seock Hwan Choi, Jun Nyung Lee, Hyun Tae Kim, Tae-Hwan Kim, Eun Sang Yoo, Ta Prostate International.2023; 11(1): 34. CrossRef
Prognostic roles of leptin‐signaling proteins, PD‐L1, and tumor‐infiltrating lymphocytes in surgically‐resected biliary tract cancers Sun‐ju Byeon, Mee Soo Chang, Hwa Jin Cho, Jeong Hwan Park, Ki Hwan Kim, Jin Hyun Park, In Sil Choi, Won Kim, Dong‐Seok Han, Hye Seong Ahn, Seung Chul Heo Journal of Surgical Oncology.2023; 127(4): 587. CrossRef
SLC17A9-PTHLH-EMT axis promotes proliferation and invasion of clear renal cell carcinoma Weiquan Li, Ning Xu, Xiangui Meng, Hongwei Yuan, Tiexi Yu, Qi Miao, Hongmei Yang, Bo Hai, Wen Xiao, Xiaoping Zhang iScience.2023; 26(1): 105764. CrossRef
Effects of a Post-Traumatic Growth Program on Young Korean Breast Cancer Survivors Ka Ryeong Bae, Wi-Young So, Seyong Jang Healthcare.2023; 11(1): 140. CrossRef
Cost-effectiveness of hyperthermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III-IV ovarian cancer from a randomized controlled phase III trial in Korea (KOV-HIPEC-01) Ji Hyun Kim, Sung-Youn Chun, Dong-eun Lee, Yo Han Woo, Suk-Joon Chang, Sang-Yoon Park, Yoon Jung Chang, Myong Cheol Lim Gynecologic Oncology.2023; 170: 19. CrossRef
Does the presence of a micropapillary component predict worse prognosis in pathological stage IA lung adenocarcinoma? Yan Wang, Wenpeng Song, Xin Wang, Guowei Che Pathology - Research and Practice.2023; 242: 154314. CrossRef
Investigation of the female infertility risk associated with anti-cancer therapy Atiye Lavafian, Parmida Sadat Pezeshki, Nima Rezaei Clinical and Translational Oncology.2023; 25(7): 1893. CrossRef
Lung Imaging Reporting and Data System (Lung-RADS) in Radiology: Strengths, Weaknesses and Improvement Gong Yong Jin Journal of the Korean Society of Radiology.2023; 84(1): 34. CrossRef
Deep learning approach to detection of colonoscopic information from unstructured reports Donghyeong Seong, Yoon Ho Choi, Soo-Yong Shin, Byoung-Kee Yi BMC Medical Informatics and Decision Making.2023;[Epub] CrossRef
Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC) Jieun Lee Journal of Clinical Medicine.2023; 12(4): 1524. CrossRef
Association between dietary habits and incident thyroid cancer: A prospective cohort study Linh Thi Dieu Nguyen, Madhawa Gunathilake, Jeonghee Lee, Jeongseon Kim Frontiers in Nutrition.2023;[Epub] CrossRef
Regional lymph node recurrence after stereotactic body radiation therapy for lung cancer: Patterns of recurrence, treatment approaches, and clinical outcomes (KROG 21-09) Tae Hoon Lee, Hyunju Shin, Yong Chan Ahn, Min Kyu Kang, Changhoon Song, Woo Chul Kim, Sung Ho Moon, Jin Hee Kim, Jaeho Cho, Hae Jin Park, Heui Kwan Lee, Byoung Hyuck Kim, Hak Jae Kim Radiotherapy and Oncology.2023; 183: 109572. CrossRef
Addition of metformin for non-small cell lung cancer patients receiving antineoplastic agents Yan Wang, Yuanyuan Hu, Ting Wang, Guowei Che, Lu Li Frontiers in Pharmacology.2023;[Epub] CrossRef
Parental Factors Affecting Decision to Vaccinate Their Daughters against Human Papillomavirus Yoon Park, Moran Ki, Hyunju Lee, Jae-Kwan Lee, Jin-Kyoung Oh Cancer Prevention Research.2023; 16(3): 133. CrossRef
Underuse of Gastric Cancer Screening Services among Koreans with Type 2 Diabetes Kumban Walter Chuck, Seri Hong, Yunhwan Lee Healthcare.2023; 11(7): 927. CrossRef
Association of Dietary Fiber Intake With Gastrointestinal Tract Cancer Among Korean Adults Shinyoung Jun, Jeonghee Lee, Jeongseon Kim JAMA Network Open.2023; 6(3): e234680. CrossRef
Prognostic value of deep learning–based fibrosis quantification on chest CT in idiopathic pulmonary fibrosis Ju Gang Nam, Yunhee Choi, Sang-Min Lee, Soon Ho Yoon, Jin Mo Goo, Hyungjin Kim European Radiology.2023; 33(5): 3144. CrossRef
Effective Timing of Introducing an Inpatient Smoking Cessation Program to Cancer Patients Yu-Ri Choe, Ji-Won Choi, Ju-Ri Jeong, Hye-Mi Doh, Mi-Lee Kim, Min-Seol Nam, Hee-Ji Kho, Ha-Young Park, Hye-Ran Ahn, Sun-Seog Kweon, Yu-Il Kim, In-Jae Oh Yonsei Medical Journal.2023; 64(4): 251. CrossRef
Stereotactic Body Radiation Therapy for Pulmonary Metastasis from Colorectal Adenocarcinoma: Biologically Effective Dose 150 Gy is Preferred for Tumour Control T.H. Lee, H.-C. Kang, E.K. Chie, H.J. Kim, H.-G. Wu, J.H. Lee, K.S. Kim Clinical Oncology.2023; 35(6): e384. CrossRef
High-Resolution Tactile-Sensation Diagnostic Imaging System for Thyroid Cancer So-Hyun Cho, Su-Min Lee, Na-Young Lee, Byoung Chul Ko, Hojeong Kim, Dae-Jin Jang, Jong-Ha Lee Sensors.2023; 23(7): 3451. CrossRef
Quality Assessment and Trend for Breast Cancer Treatment Practice across South Korea Based on Nationwide Analysis of Korean Health Insurance Data during 2013-2017 Kyu Hye Choi, Soo-Yoon Sung, Sea-Won Lee, Ye Won Jeon, Sung Hwan Kim, Jong Hoon Lee Cancer Research and Treatment.2023; 55(2): 570. CrossRef
Patterns and Longitudinal Changes in the Practice of Breast Cancer Radiotherapy in Korea: Korean Radiation Oncology Group 22-01 Hae Jin Park, Kyubo Kim, Yong Bae Kim, Jee Suk Chang, Kyung Hwan Shin Journal of Breast Cancer.2023; 26(3): 254. CrossRef
Sex-specific effects of fruit, vegetable, and red meat intake on the risk of gastric and esophageal cancer in a large cohort Su Youn Nam, Junwoo Jo, Seong Woo Jeon, Hyonho Chun Digestive and Liver Disease.2023; 55(10): 1403. CrossRef
Novel thrombospondin-1 transcript exhibits distinctive expression and activity in thyroid tumorigenesis Yukyung Hong, Ilju Kim, Hyunjin Moon, Jaehak Lee, Pattawika Lertpatipanpong, Chang Hwan Ryu, Yuh-Seog Jung, Jungirl Seok, Yonghwan Kim, Junsun Ryu, Seung Joon Baek Oncogene.2023; 42(22): 1832. CrossRef
Comparison of a Tobacco-Specific Carcinogen in Tobacco Cigarette, Electronic Cigarette, and Dual Users Jae-woo Lee, Sukil Kim Journal of Korean Medical Science.2023;[Epub] CrossRef
Licochalcone A Exerts Anti-Cancer Activity by Inhibiting STAT3 in SKOV3 Human Ovarian Cancer Cells Jeonghyeon Seo, Da Eun Lee, Seong Mi Kim, Eunjung Kim, Jin-Kyung Kim Biomedicines.2023; 11(5): 1264. CrossRef
Conization before radical hysterectomy in patients with early-stage cervical cancer: A Korean multicenter study (COBRA-R) Se Ik Kim, So Hyun Nam, Suhyun Hwangbo, Yeorae Kim, Hyun-Woong Cho, Dong Hoon Suh, Jae Yun Song, Jae-Weon Kim, Chel Hun Choi, Dae-Yeon Kim, Maria Lee Gynecologic Oncology.2023; 173: 88. CrossRef
Association between changes in having of cancer patients in the family and depression: A longitudinal panel study Yun Seo Jang, Na-Young Yoon, Kyungduk Hurh, Eun-Cheol Park, Min Jin Ha Journal of Affective Disorders.2023; 333: 482. CrossRef
Risk factors of recurrence in TNM stage I colorectal cancer Jin-Hee Paik, Chun-Geun Ryu, Dae-Yong Hwang Annals of Surgical Treatment and Research.2023; 104(5): 281. CrossRef
Fertility-sparing hormonal treatment in patients with stage I endometrial cancer of grade 2 without myometrial invasion and grade 1–2 with superficial myometrial invasion: Gynecologic Oncology Research Investigators coLLaborAtion study (GORILLA-2001) A Jin Lee, Eun Jung Yang, Nam Kyeong Kim, Yeorae Kim, Dong Hoon Suh, Jeeyeon Kim, Joo-Hyuk Son, Tae-Wook Kong, Suk-Joon Chang, Dong Won Hwang, Soo Jin Park, Hee Seung Kim, Ji Geun Yoo, Sung Jong Lee, Yoo-Young Lee, Seung-Hyuk Shim Gynecologic Oncology.2023; 174: 106. CrossRef
Gut microbiome associated with low anterior resection syndrome after rectal cancer surgery Min Jung Kim, Soyoung Park, Ji Won Park, Jinsun Choi, Hyo Jun Kim, Han-Ki Lim, Seung-Bum Ryoo, Kyu Joo Park, Yosep Ji, Seung-Yong Jeong Scientific Reports.2023;[Epub] CrossRef
Increased risk of pancreatic, thyroid, prostate and breast cancers in men with a family history of breast cancer: A population‐based study Huiyeon Song, Yoon Suk Jung, Thi Xuan Mai Tran, Chang Mo Moon, Boyoung Park International Journal of Cancer.2023; 153(5): 950. CrossRef
National Cancer Control Plan of the Korea: Current Status and the Fourth Plan (2021-2025) Kyu-Tae Han, Jae Kwan Jun, Jeong-Soo Im Journal of Preventive Medicine and Public Health.2023; 56(3): 205. CrossRef
Breast Cancer Statistics in Korea, 2019 Jung Eun Choi, Zisun Kim, Chan Sub Park, Eun Hwa Park, Sae Byul Lee, Se Kyung Lee, Young Jin Choi, Jaihong Han, Kyu-Won Jung, Hee Jeong Kim, Hyun-Ah Kim Journal of Breast Cancer.2023; 26(3): 207. CrossRef
Early-onset stroke among people with disabilities: a national database study in South Korea from 2008 to 2017 Hee Soo Yang, So Young Kim, Min Jae Jo, Yeon Yong Kim, Jong Hyock Park The Lancet Regional Health - Western Pacific.2023; 38: 100819. CrossRef
Importance of Early Surveillance Endoscopy in Patients at a High Risk of Gastric Cancer Sang Hoon Kim The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2023; 23(2): 151. CrossRef
Impact of pre‐ and post‐diagnosis physical activity on the mortality of patients with cancer: Results from the Health Examinees‐G study in Korea Jaesung Choi, Joo‐Yong Park, Ji‐Eun Kim, Miyoung Lee, Kyuwan Lee, Jong‐Koo Lee, Daehee Kang, Aesun Shin, Ji‐Yeob Choi Cancer Medicine.2023; 12(15): 16591. CrossRef
Significance of The Regular Publication of Statistics on National Health Indicators in Academic Journals and The Prospects of Korea National Antimicrobial Use Analysis System (KONAS) Bongyoung Kim, Yong Chan Kim, Hyung-Sook Kim, Se Yoon Park, Jun Yong Choi Infection & Chemotherapy.2023; 55(2): 306. CrossRef
Predictive role of pretreatment skeletal muscle mass index for long-term survival of bladder cancer patients: A meta-analysis Qian Yuan, Jianrong Hu, Feng Yuan, Jingjing An, Andrea D’Aviero PLOS ONE.2023; 18(6): e0288077. CrossRef
Is Fragmented Cancer Care Associated With Medical Expenditure? Nationwide Evidence From Patients With Lung Cancer Using National Insurance Claim Data Kyu-Tae Han, Sun Jung Kim International Journal of Public Health.2023;[Epub] CrossRef
Genomic and evolutionary characteristics of metastatic gastric cancer by routes Jae Eun Lee, Ki Tae Kim, Su-Jin Shin, Jae-Ho Cheong, Yoon Young Choi British Journal of Cancer.2023; 129(4): 672. CrossRef
The incidence and risk factors of occult malignancy in patients receiving vaginal hysterectomy for pelvic organ prolapse Soo Min Ryu, Jeong Soo Cho, Mi Kyung Kong, Sang Wook Bai International Urogynecology Journal.2023; 34(11): 2719. CrossRef
Overview of the National Cancer Screening Program for Colorectal Cancer in Korea over 14 Years (2004-2017) Bomi Park, Eun Young Her, Kyeongmin Lee, Fatima Nari, Jae Kwan Jun, Kui Son Choi, Mina Suh Cancer Research and Treatment.2023; 55(3): 910. CrossRef
Urologic malignancies that cause hematuria Sung Jin Kim, Myungchan Park, Sangjun Yoo Journal of the Korean Medical Association.2023; 66(6): 363. CrossRef
Right Then, Wrong Now: Early-Onset Colorectal Cancer in Korea Aesun Shin, Kyu-Won Jung, Seung-Yong Jeong Cancer Research and Treatment.2023; 55(3): 1058. CrossRef
Single-center study on clinicopathological and typical molecular pathologic features of metastatic brain tumor Su Hwa Kim, Young Suk Lee, Sung Hak Lee, Yeoun Eun Sung, Ahwon Lee, Jun Kang, Jae-Sung Park, Sin Soo Jeun, Youn Soo Lee Journal of Pathology and Translational Medicine.2023; 57(4): 217. CrossRef
Crataegus pinnatifida Bunge root extract induces apoptosis of murine lung carcinoma cells in vitro Minjeong Kwon, Jongbeom Chae, Ju-Ock Nam Journal of Applied Biological Chemistry.2023;[Epub] CrossRef
Changes in spatial clusters of cancer incidence and mortality over 15 years in South Korea: Implication to cancer control Cham Thi Nguyen, Insang Song, Inkyung Jung, Yoon‐Jung Choi, Sun‐Young Kim Cancer Medicine.2023; 12(16): 17418. CrossRef
Factors Associated with Dietary Habit Changes in Korean Stomach Cancer Survivors after Cancer Treatment Junhee Park, Jiyoung Kim, Dong Wook Shin, Jinyoung Shin, Belong Cho, Yun-Mi Song Nutrients.2023; 15(14): 3268. CrossRef
Individual and joint effect of socioeconomic status and lifestyle factors on cancer in Korea Chi Lan Tran, Kui Son Choi, Sun‐Young Kim, Jin‐Kyoung Oh Cancer Medicine.2023; 12(16): 17389. CrossRef
The Effects of Coping Strategies Between Uncertainty and Quality of Life of Korean Women With Gynecological Cancer Eungil Ko, Yaelim Lee Advances in Nursing Science.2023;[Epub] CrossRef
Racial differences in long-term social, physical, and psychological health among adolescent and young adult cancer survivors Sooyeon Kim, Juhee Cho, Dong Wook Shin, Su-Min Jeong, Danbee Kang BMC Medicine.2023;[Epub] CrossRef
Changes in metabolic syndrome and the risk of breast and endometrial cancer according to menopause in Korean women Thi Xuan Mai Tran, Soyeoun Kim, Boyoung Park Epidemiology and Health.2023; 45: e2023049. CrossRef
Operational Definitions of Colorectal Cancer in the Korean National Health Insurance Database Hyeree Park, Yu Rim Kim, Yerin Pyun, Hyundeok Joo, Aesun Shin Journal of Preventive Medicine and Public Health.2023; 56(4): 312. CrossRef
Thromboembolic events in patients who received adjuvant chemotherapy for gastric cancer: a single-center retrospective study Tae-Hwan Kim, Jin-Hyuk Choi, Sang Min Jeon, Yong Won Choi, Minsuk Kwon, Hyun Woo Lee, Seok Yun Kang, Mi Sun Ahn, Sang-Yong Son, Hoon Hur, Sang-Uk Han, Seung-Soo Sheen Gastric Cancer.2023; 26(6): 1012. CrossRef
Comprehensive Analysis of Iron Deficiency Anemia and Its Related Disorders in Premenopausal Women Based on a Propensity Score Matching Case Control Study Using National Health Insurance Service Database in Korea Hyun Jung Lee, Haeyong Pak, Jae Joon Han, Myung Hee Chang Journal of Korean Medical Science.2023;[Epub] CrossRef
Edible mushroom intake and risk of all-cause and cause-specific mortality: results from the Korean Genome and Epidemiology Study (KoGES) Cohort Hyein Jung, JiAe Shin, Kyungjoon Lim, Sangah Shin Food & Function.2023; 14(19): 8829. CrossRef
Risk of Subsequent Primary Cancer in Thyroid Cancer Survivors: A Nationwide Population-Based Study Min-Su Kim, Sang Jun Lee, Myeong Hoon Lee, Jay Hyug Choi, Hyun Wook Han, Young Shin Song Diagnostics.2023; 13(18): 2903. CrossRef
The effect of the introduction of the national lung cancer screening program on short-term mortality in Korea Woorim Kim, Sang Chul Lee, Woo-Ri Lee, Sungyoun Chun Lung Cancer.2023; 186: 107412. CrossRef
Cluster of lifestyle risk factors for stomach cancer and screening behaviors among Korean adults Thao Thi Kim Trinh, Kyeongmin Lee, Jin-Kyoung Oh, Mina Suh, Jae Kwan Jun, Kui Son Choi Scientific Reports.2023;[Epub] CrossRef
The role of LOXL2 induced by glucose metabolism-activated NF-κB in maintaining drug resistance through EMT and cancer stemness in gemcitabine-resistant PDAC Yun Sun Lee, Hyung Sun Kim, Hyo Jung Kim, Hyeon Woong Kang, Da Eun Lee, Myeong Jin Kim, Woosol Chris Hong, Ju Hyun Kim, Minsoo Kim, Jae-Ho Cheong, Joon Seong Park Journal of Molecular Medicine.2023; 101(11): 1449. CrossRef
Analysis of the Spread of Misinformation about Lung Cancer on YouTube: Based on Source of Information Hangsoo Park, EunKyo Kang, Yeol Kim, HyoRim Ju Korean Journal of Family Practice.2023; 13(3): 152. CrossRef
Zinc intake, SLC30A8 rs3802177 polymorphism, and colorectal cancer risk in a Korean population: a case–control study Linh Thi Dieu Nguyen, Madhawa Gunathilake, Jeonghee Lee, Jae Hwan Oh, Hee Jin Chang, Dae Kyung Sohn, Aesun Shin, Jeongseon Kim Journal of Cancer Research and Clinical Oncology.2023; 149(18): 16429. CrossRef
Nivolumab as maintenance therapy following platinum‐based chemotherapy in EGFR‐mutant lung cancer patients after tyrosine kinase inhibitor failure: A single‐arm, open‐label, phase 2 trial Jiwon Kim, Chang‐Min Choi, Wonjun Ji, Jae Cheol Lee Thoracic Cancer.2023; 14(31): 3080. CrossRef
Exploring the past, present, and future of postoperative radiotherapy for N2 stage non-small cell lung cancer Byoung Hyuck Kim, Jae Sik Kim, Hak Jae Kim Radiation Oncology Journal.2023; 41(3): 144. CrossRef
Clinical implications of RAB13 expression in pan-cancer based on multi-databases integrative analysis Xu-dong Zhang, Zhong-yuan Liu, Kai Luo, Xiang-kun Wang, Mao-sen Wang, Shuai Huang, Ren-feng Li Scientific Reports.2023;[Epub] CrossRef
Post-percutaneous core needle biopsy sputum cytology: diagnostic value and factors for positive prediction in diagnosing malignancy Sang Kyu Lee, Hee Kang, Min Jung Jung, Sekyoung Park, Ki Nam Lee Kosin Medical Journal.2023; 38(3): 201. CrossRef
Rigid bronchoscopic intervention for malignant central airway obstruction:
A narrative review Byeong-Ho Jeong, Hojoong Kim Precision and Future Medicine.2023; 7(3): 95. CrossRef
Optimal Cutoff Values of the Contact Angle of Tumor on Sonography System for Predicting Extrathyroidal Extension of Papillary Thyroid Carcinoma by Tumor Location Ik Beom Shin, Do Hoon Koo, Dong Sik Bae Clinical Medicine Insights: Oncology.2023;[Epub] CrossRef
Large colonic lipoma with a laterally spreading tumor treated by endoscopic submucosal dissection: A case report Jun Yong Bae, Hun Kyu Kim, Yee Jin Kim, Se Woong Kim, Youngeun Lee, Chang Beom Ryu, Moon Sung Lee World Journal of Clinical Cases.2023; 11(26): 6194. CrossRef
Increased Screening Rates for Thyroid Cancer Among Residents Living Near Nuclear Power Plants Ga Bin Lee, Soojin Park, Won Il Jang, Sunhoo Park, Jae Kwan Jun, Songwon Seo Journal of Korean Medical Science.2023;[Epub] CrossRef
Cancer risks in patients with psoriasis administered biologics therapy: a nationwide population-based study Joon Min Jung, Ye-Jee Kim, Sung Eun Chang, Mi Woo Lee, Chong Hyun Won, Woo Jin Lee Journal of Cancer Research and Clinical Oncology.2023; 149(19): 17093. CrossRef
Final Report on Real-World Effectiveness of Sequential Afatinib and Osimertinib in EGFR-Positive Advanced Non–Small Cell Lung Cancer: Updated Analysis of the RESET Study Taeyun Kim, Tae Won Jang, Chang Min Choi, Mi-Hyun Kim, Sung Yong Lee, Yoon Soo Chang, Kye Young Lee, Seung Joon Kim, Sei Hoon Yang, Jeong Seon Ryu, Jeong Eun Lee, Shin Yup Lee, Chan Kwon Park, Sang Hoon Lee, Seung Hun Jang, Seong Hoon Yoon, Hyung-Joo Oh Cancer Research and Treatment.2023; 55(4): 1152. CrossRef
The Multidomain Metaverse Cancer Care Digital Platform: Development and Usability Study Sunghak Kim, Timothy Jung, Dae Kyung Sohn, Yoon Chae, Young Ae Kim, Seung Hyun Kang, Yujin Park, Yoon Jung Chang JMIR Serious Games.2023; 11: e46242. CrossRef
Knowledge mapping of immunotherapy for thyroid cancer from 1980 to 2022: A review Ran Ding, Hongguan Jiao, Yuanlin Piao, Weiyi Tian Medicine.2023; 102(39): e35506. CrossRef
Alzheimer’s Disease and Different Types of Cancer Likelihood: Unveiling Disparities and Potential Protective Effects in a Korean Cohort Study Ho Suk Kang, Ji Hee Kim, Hyun Lim, Joo-Hee Kim, Hye-Mi Noh, Hyo Geun Choi, Kyueng-Whan Min, Nan Young Kim, Mi Jung Kwon Cancers.2023; 15(18): 4615. CrossRef
Association between gut microbial change and acute gastrointestinal toxicity in patients with prostate cancer receiving definitive radiation therapy Bum‐Sup Jang, Moon Gyu Chung, Dong Soo Lee Cancer Medicine.2023; 12(22): 20727. CrossRef
Health Behaviors of Cancer Survivors According to the Employment Status and Occupation: A Cross-Sectional Study Ka Ryeong Bae, Wi-Young So, Su Jung Lee Healthcare.2023; 11(22): 2974. CrossRef
Predictive factors of lymph node metastasis in papillary thyroid cancer Woo Jin Song, In Chan Um, Sa Rang Kwon, Jin Ho Lee, Hye Won Lim, Yong Uk Jeong, Seung Min Chung, Jun Sung Moon, Ji Sung Yoon, Kyu Chang Won, Hyoung Woo Lee, Adeel Ahmad Khan PLOS ONE.2023; 18(11): e0294594. CrossRef
Exocrine pancreatic cancer as a second primary malignancy: A population-based study Mee Joo Kang, Jiwon Lim, Sung-Sik Han, Hyeong Min Park, Sung Chun Cho, Sang-Jae Park, Sun-Whe Kim, Young-Joo Won Annals of Hepato-Biliary-Pancreatic Surgery.2023; 27(4): 415. CrossRef
Disparities in Cancer Incidence across Income Levels in South Korea Su-Min Jeong, Kyu-Won Jung, Juwon Park, Nayeon Kim, Dong Wook Shin, Mina Suh Cancers.2023; 15(24): 5898. CrossRef
Frailty in Geriatric Patients with Head and Neck Cancer and its Implication in Survivorship Minsu Kwon Korean Society for Head and Neck Oncology.2023; 39(2): 1. CrossRef
Application of Artificial Intelligence in Breast Imaging: Current Landscape and Prospects Hee Jeong Kim, Hak Hee Kim Korean Journal of Family Practice.2023; 13(4): 196. CrossRef
Disparities of health expenditure associated with the experience of admission in long-term care hospital among patients with colorectal cancer in South Korea: A generalized estimating equation Woo-Ri Lee, Noorhee Son, Ki-Bong Yoo, Kyu-Tae Han, Sina Azadnajafabad PLOS ONE.2023; 18(12): e0296170. CrossRef
Interaction between vitamin E intake and a COMT gene variant on colorectal cancer risk among Korean adults: a case-control study Shinyoung Jun, Madhawa Gunathilake, Jeonghee Lee, Jae Hwan Oh, Hee Jin Chang, Dae Kyung Sohn, Aesun Shin, Jeongseon Kim Epidemiology and Health.2023; 45: e2023100. CrossRef
Parental intention to vaccinate daughters with the human papillomavirus vaccine in Korea: a nationwide cross-sectional survey Yejin Ha, Kyeongmin Lee, Bomi Park, Mina Suh, Jae Kwan Jun, Kui Son Choi Epidemiology and Health.2023; 45: e2023076. CrossRef
Adherence to the World Cancer Research Fund/American Institute for Cancer Research and Korean Cancer Prevention Guidelines and cancer risk: a prospective cohort study from the Health Examinees-Gem study Jeeyoo Lee, Aesun Shin, Woo-Kyoung Shin, Ji-Yeob Choi, Daehee Kang, Jong-Koo Lee Epidemiology and Health.2023; 45: e2023070. CrossRef
Genetically determined alcohol consumption and cancer risk in Korea Keum Ji Jung, Ji Woo Baek, Sang Yop Shin, Sun Ha Jee Epidemiology and Health.2023; 45: e2023077. CrossRef
Dietary intake and cancer incidence in Korean adults: a systematic review and meta-analysis of observational studies Ji Hyun Kim, Shinyoung Jun, Jeongseon Kim Epidemiology and Health.2023; 45: e2023102. CrossRef
Comparison of Long-Term Survival Between cT1N0 Stage Esophageal Cancer Patients Receiving Endoscopic Dissection and Esophagectomy: A Meta-Analysis Wei Lu, Peng Li, Wu Wen, Yi Jian Frontiers in Surgery.2022;[Epub] CrossRef
Feasibility of Indocyanine Green Fluorescence Lymph Node Mapping for Radical Colectomy of Mid-Transverse and Left-Sided Colon Cancer Soo Yeun Park, Jun Seok Park, Hye Jin Kim, Gyu-Seog Choi Annals of Robotic and Innovative Surgery.2022; 3(1): 1. CrossRef
A New Chemotherapy Paradigm in Advanced Esophageal Cancer Jang Ho Cho Journal of Digestive Cancer Research.2022; 10(1): 43. CrossRef
Current Evidence for a Paradigm Shift in Gastric Cancer Prevention From Endoscopic Screening toHelicobacter pyloriEradication in Korea Young-Il Kim, Il Ju Choi Journal of Gastric Cancer.2022; 22(3): 169. CrossRef
Particulate Matter Exposure after a Cancer Diagnosis and All-Cause Mortality in a Regional Cancer Registry-Based Cohort in South Korea Sang-Yong Eom, Yong-Dae Kim, Heon Kim International Journal of Environmental Research and Public Health.2022; 19(16): 9875. CrossRef
Open versus minimally invasive radical hysterectomy for early cervical cancer: A two-center retrospective cohort study with pathologic review of usual-type adenocarcinoma and adenosquamous carcinoma Yeorae Kim, Se Ik Kim, Hyojin Kim, Maria Lee, Hee Seung Kim, Kidong Kim, Hyun Hoon Chung, Jae Hong No, Yong Beom Kim, Jae-Weon Kim, Noh Hyun Park, Yong-Sang Song, Cheol Lee, Dong Hoon Suh Gynecologic Oncology.2022; 167(1): 28. CrossRef
Healthcare vulnerability disparities in pancreatic cancer treatment and mortality using the Korean National Sample Cohort: a retrospective cohort study Sung Hoon Jeong, Hyeon Ji Lee, Choa Yun, Il Yun, Yun Hwa Jung, Soo Young Kim, Hee Seung Lee, Sung-In Jang BMC Cancer.2022;[Epub] CrossRef
Incidence, mortality, and survival of liver cancer using Korea central cancer registry database: 1999-2019 Sung Yeon Hong, Mee Joo Kang, Taegyu Kim, Kyu-Won Jung, Bong-Wan Kim Annals of Hepato-Biliary-Pancreatic Surgery.2022; 26(3): 211. CrossRef
Incidence, mortality and survival of gallbladder, extrahepatic bile duct, and pancreatic cancer using Korea central cancer registry database: 1999-2019 Mee Joo Kang, E Hwa Yun, Kyu-Won Jung, Sang-Jae Park Annals of Hepato-Biliary-Pancreatic Surgery.2022; 26(3): 220. CrossRef
The Effects of Lifestyle and Self-rated Health on Mental Health of Breast Cancer Survivors: Using Propensity Score Matching Approach Hyeng Sook Yoon, Eunjung Ryu Korean Journal of Adult Nursing.2022; 34(4): 369. CrossRef
Factors Associated with Cyto-Histological Misinterpretation of Cervical Smear according to Menopausal Status Min Seong Choi, Young Jin Lee, Eun Hyun Lee, Yong Il Ji, Min Jeong Park Journal of Menopausal Medicine.2022; 28(2): 78. CrossRef
2021 Consensus Statements on the Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma From the Korean Renal Cancer Study Group (KRoCS) Chan Ho Lee, Minyong Kang, Cheol Kwak, Sung Han Kim, Jung Kwon Kim, Jae Young Park, Seong Il Seo, Ill Young Seo, Jungyo Suh, Wan Song, Cheryn Song, Hyeong Dong Yuk, Sangchul Lee, Hyung Ho Lee, Jinsoo Chung, Chang Wook Jeong, Jung Ki Jo, Chang Il Choi, Seo The Korean Journal of Urological Oncology.2022; 20(3): 151. CrossRef
Cancer Rehabilitation Fact Sheet in Korea Jin A Yoon, Bo Young Hong Annals of Rehabilitation Medicine.2022; 46(4): 155. CrossRef
Stereotactic body radiation therapy for elderly patients with small hepatocellular carcinoma: a retrospective observational study Jeong Yun Jang, Jinhong Jung, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Jin-hong Park, Sang Min Yoon Journal of Liver Cancer.2022; 22(2): 136. CrossRef
The Feasibility of Stereotactic Body Proton Beam Therapy for Pancreatic Cancer Hyunju Shin, Jeong Il Yu, Hee Chul Park, Gyu Sang Yoo, Sungkoo Cho, Joon Oh Park, Kyu Taek Lee, Kwang Hyuck Lee, Jong Kyun Lee, Joo Kyung Park, Jin Seok Heo, In Woong Han, Sang Hyun Shin Cancers.2022; 14(19): 4556. CrossRef
Association between Obesity Indexes and Thyroid Cancer Risk in Korean Women: Nested Case–Control Study Yoonyoung Jang, Taehwa Kim, Brian H. S. Kim, Boyoung Park Cancers.2022; 14(19): 4712. CrossRef
Impact of Cardiovascular Diseases on Mortality in Gastric Cancer Patients with Preexisting Chronic Disease Kyu-Tae Han, Dong Wook Kim, Woorim Kim Yonsei Medical Journal.2022; 63(11): 1043. CrossRef
Direction of diagnosis and treatment improvement in colorectal cancer In Ja Park Journal of the Korean Medical Association.2022; 65(9): 540. CrossRef
Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: A meta-analysis Se Ik Kim, Ji Hyun Kim, Sanghee Lee, Hyunsoon Cho, Willemien J. van Driel, Gabe S. Sonke, Robert E. Bristow, Sang-Yoon Park, Christina Fotopoulou, Myong Cheol Lim Gynecologic Oncology.2022; 167(3): 547. CrossRef
Exposure to multiple trace elements and thyroid cancer risk in Chinese adults: A case-control study Jia-liu He, Hua-bing Wu, Wen-lei Hu, Jian-jun Liu, Qian Zhang, Wei Xiao, Ming-jun Hu, Ming Wu, Fen Huang International Journal of Hygiene and Environmental Health.2022; 246: 114049. CrossRef
Respiratory Tract Cancer Incidences across Industry Groups: A Nationwide Cohort Study with More Than 70 Million Person-Years of Follow-Up Seong-Uk Baek, Woo-Ri Lee, Ki-Bong Yoo, Jun-Hyeok Choi, Kyung-Eun Lee, Wanhyung Lee, Jin-Ha Yoon Cancers.2022; 14(21): 5219. CrossRef
Update on Diagnosis and Treatment of Colorectal
Cancer Chan Wook Kim The Ewha Medical Journal.2022;[Epub] CrossRef
Analysis of prognostic factors through survival rate analysis of oral squamous cell carcinoma patients treated at the National Cancer Center: 20 years of experience Yong-Seok Choi, Min Gyeong Kim, Jong-Ho Lee, Joo-Yong Park, Sung-Weon Choi Journal of the Korean Association of Oral and Maxillofacial Surgeons.2022; 48(5): 284. CrossRef
Colorectal cancer mortality trends in the era of cancer survivorship in Korea: 2000–2020 Min Hyun Kim, Sanghee Park, Nari Yi, Bobae Kang, In Ja Park Annals of Coloproctology.2022; 38(5): 343. CrossRef
Clinical Efficacy of Hypofractionated Proton Beam Therapy for Intrahepatic Cholangiocarcinoma Tae Hyun Kim, Sang Myung Woo, Woo Jin Lee, Jung Won Chun, Yu Ri Cho, Bo Hyun Kim, Young-Hwan Koh, Sang Soo Kim, Eun Sang Oh, Do Yeul Lee, Sung Uk Lee, Yang-Gun Suh, Sung Ho Moon, Joong-Won Park Cancers.2022; 14(22): 5561. CrossRef
Progression of Low-Risk Papillary Thyroid Microcarcinoma During Active Surveillance: Interim Analysis of a Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma in Korea Eun Kyung Lee, Jae Hoon Moon, Yul Hwangbo, Chang Hwan Ryu, Sun Wook Cho, June Young Choi, Eun-Jae Chung, Woo-Jin Jeong, Yuh-Seog Jung, Junsun Ryu, Su-jin Kim, Min Joo Kim, Yeo Koon Kim, Chang Yoon Lee, Ji Ye Lee, Hyeong Won Yu, Jeong Hun Hah, Kyu Eun Lee, Thyroid.2022; 32(11): 1328. CrossRef
The risk of osteoporotic fractures after gastrectomy: Findings from the Korean national sample cohort database (2002-2019) Il Yun, Kyungduk Hurh, Sung Hoon Jeong, Eun-Cheol Park, Sung-In Jang Frontiers in Oncology.2022;[Epub] CrossRef
Impact of modifiable reproductive factors on cancer incidence and mortality in Korea: a systematic review protocol Seo-Hee Kim, Mi Ah Han BMJ Open.2022; 12(11): e067826. CrossRef
Traditional Korean Medicine Treatment for Sequelae After Surgery in Prostate Cancer Patients: Two Case Report Kwon-jun Jang, Jung-min Yang, Woo-seok Hwang, Beom-joon Lee The Journal of Internal Korean Medicine.2022; 43(5): 795. CrossRef
NGS-based targeted gene mutational profiles in Korean patients with pancreatic cancer Kwangrok Jung, Sejoon Lee, Hee Young Na, Ji-Won Kim, Jong-Chan Lee, Jin-Hyeok Hwang, Jin Won Kim, Jaihwan Kim Scientific Reports.2022;[Epub] CrossRef
A Survey on the Quality of Life of Prostate Cancer Patients in Korean Prostate Cancer Patients Association Yun-Sok Ha, Kwang Taek Kim, Wook Nam, Hongzoo Park, Sangjun Yoo, Chan Ho Lee, Ho Seok Chung, Woo Suk Choi, Jiyoun Kim, Jaeeun Shin, Jeong Hyun Kim, Cheol Kwak The Korean Journal of Urological Oncology.2022; 20(4): 265. CrossRef
Comparison of Gastric Cancer Screening Strategies between Helicobacter pylori-infected, -eradicated, and -naive Individuals Sun-Young Lee The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2022; 22(4): 313. CrossRef
Omission of chemotherapy for hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer: patterns of treatment and outcomes from the Korean Breast Cancer Society Registry Hannah Lois Kangleon-Tan, Jongmin Sim, Ji Young You, Eun-Shin Lee, Haemin Lee, Sun Moon Yang, Min-Ki Seong, Eun Hwa Park, Seok Jin Nam, Min Ho Park, Seokwon Lee, Woo-Chan Park, Rogelio G. Kangleon, Crisostomo B. Dy, Soo Youn Bae, Seung Pil Jung Annals of Surgical Treatment and Research.2022; 103(6): 313. CrossRef
Does fragmented cancer care affect survival? Analysis of gastric cancer patients using national insurance claim data Dong-Woo Choi, Sun Jung Kim, Dong Jun Kim, Yoon-Jung Chang, Dong Wook Kim, Kyu-Tae Han BMC Health Services Research.2022;[Epub] CrossRef
Clinical utilization of radiation therapy in Korea between 2017 and 2019 Eunji Kim, Won Il Jang, Kwangmo Yang, Mi-Sook Kim, Hyung Jun Yoo, Eun Kyung Paik, Heejin Kim, Jaesun Yoon Radiation Oncology Journal.2022; 40(4): 251. CrossRef
Effects of Education Program for Combined Management of Lymphedema with regard to Breast Cancer Patients with Axillary Lymph Node Dissection: A Quasi-Experimental Study Soohyun Kim, Eunjung Ryu Asian Oncology Nursing.2022; 22(4): 214. CrossRef
The National Hospice and Palliative Care registry in Korea Kyuwoong Kim, Bohyun Park, Bonju Gu, Eun Jeong Nam, Sue Hyun Kye, Jin Young Choi Epidemiology and Health.2022; 44: e2022079. CrossRef
Awareness of and practice toward cancer prevention recommendations: results of the Korean National Cancer Prevention Awareness and Practice Survey in 2021 Jin-Kyoung Oh, Eunjung Park, Byungmi Kim, Yoon-Jung Choi, E Hwa Yun, Min Kyung Lim, Jeong-Soo Im, Eun Young Park Epidemiology and Health.2022; 44: e2022068. CrossRef
Association of the inflammatory balance of diet and lifestyle with colorectal cancer among Korean adults: a case-control study Shinyoung Jun, Jeonghee Lee, Jae Hwan Oh, Hee Jin Chang, Dae Kyung Sohn, Aesun Shin, Jeongseon Kim Epidemiology and Health.2022; 44: e2022084. CrossRef
Seok Jin Kim, Yeon Jeong Kim, Sang Eun Yoon, Kyung Ju Ryu, Bon Park, Donghyun Park, Duck Cho, Hyun-Young Kim, Junhun Cho, Young Hyeh Ko, Woong-Yang Park, Won Seog Kim
Cancer Res Treat. 2023;55(1):291-303. Published online March 2, 2022
Purpose Plasma circulating tumor DNA (ctDNA) could reflect the genetic alterations present in tumor tissues. However, there is little information about the clinical relevance of cell-free DNA genotyping in peripheral T-cell lymphoma (PTCL).
Materials and Methods After targeted sequencing plasma cell-free DNA of patients with various subtypes of PTCL (n=94), we analyzed the mutation profiles of plasma ctDNA samples and their predictive value of dynamic ctDNA monitoring for treatment outcomes.
Results Plasma ctDNA mutations were detected in 53 patients (56%, 53/94), and the detection rate of somatic mutations was highest in angioimmunoblastic T-cell lymphoma (24/31, 77%) and PTCL, not otherwise specified (18/29, 62.1%). Somatic mutations were detected in 51 of 66 genes that were sequenced, including the following top 10 ranked genes: RHOA, CREBBP, KMT2D, TP53, IDH2, ALK, MEF2B, SOCS1, CARD11, and KRAS. In the longitudinal assessment of ctDNA mutation, the difference in ctDNA mutation volume after treatment showed a significant correlation with disease relapse or progression. Thus, a ≥ 1.5-log decrease in genome equivalent (GE) between baseline and the end of treatment showed a significant association with better survival outcomes than a < 1.5-log decrease in GE.
Conclusion Our results suggest the clinical relevance of plasma ctDNA analysis in patients with PTCL. However, our findings should be validated by a subsequent study with a larger study population and using a broader gene panel.
Citations
Citations to this article as recorded by
Feasibility of Circulating Tumor DNA Detection in the Cerebrospinal Fluid of Patients With Central Nervous System Involvement in Large B-Cell Lymphoma Seok Jin Kim, Jin Ju Kim, Mi Ri Park, Bon Park, Kyung Ju Ryu, Sang Eun Yoon, Won Seog Kim, Saeam Shin, Seung-Tae Lee Annals of Laboratory Medicine.2025; 45(1): 90. CrossRef
Liquid biopsy in T-cell lymphoma: biomarker detection techniques and clinical application Zongyao Huang, Yao Fu, Hong Yang, Yehan Zhou, Min Shi, Qingyun Li, Weiping Liu, Junheng Liang, Liuqing Zhu, Sheng Qin, Huangming Hong, Yang Liu Molecular Cancer.2024;[Epub] CrossRef
Feasibility of Circulating Tumor DNA Analysis in Patients with Follicular Lymphoma Sang Eun Yoon, Seung-Ho Shin, Dae Keun Nam, Junhun Cho, Won Seog Kim, Seok Jin Kim Cancer Research and Treatment.2024; 56(3): 920. CrossRef
Minimal residual disease detection in lymphoma: methods, procedures and clinical significance Sijun Zhang, Xiangyu Wang, Zhenzhen Yang, Mengjie Ding, Mingzhi Zhang, Ken H. Young, Xudong Zhang Frontiers in Immunology.2024;[Epub] CrossRef
Clinical applications of circulating tumor DNA in hematological malignancies: From past to the future Jun-Ying Li, Li-Ping Zuo, Jian Xu, Chun-Yan Sun Blood Reviews.2024; 68: 101237. CrossRef
Clinical use of circulating tumor DNA analysis in patients with lymphoma Bettina Bisig, Karine Lefort, Sylvain Carras, Laurence de Leval Human Pathology.2024; : 105679. CrossRef
A practical approach to the modern diagnosis and classification of T- and NK-cell lymphomas Laurence de Leval, Philippe Gaulard, Ahmet Dogan Blood.2024; 144(18): 1855. CrossRef
In-depth circulating tumor DNA sequencing for prognostication and monitoring in natural killer/T-cell lymphomas Jin Ju Kim, Hyun-Young Kim, Zisun Choi, So yoon Hwang, Hansol Jeong, Jong Rak Choi, Sang Eun Yoon, Won Seog Kim, Sun-Hee Kim, Hee-Jin Kim, Sang-Yong Shin, Seung-Tae Lee, Seok Jin Kim Frontiers in Oncology.2023;[Epub] CrossRef
Circulating tumor DNA in NK/T and peripheral T cell lymphoma Yu-Jia Huo, Wei-Li Zhao Seminars in Hematology.2023; 60(3): 173. CrossRef
A genetic profiling guideline to support diagnosis and clinical management of lymphomas Margarita Sánchez-Beato, Miriam Méndez, María Guirado, Lucía Pedrosa, Silvia Sequero, Natalia Yanguas-Casás, Luis de la Cruz-Merino, Laura Gálvez, Marta Llanos, Juan Fernando García, Mariano Provencio Clinical and Translational Oncology.2023; 26(5): 1043. CrossRef
Seong Hyun Jeong, Seok Jin Kim, Dok Hyun Yoon, Yong Park, Hye Jin Kang, Youngil Koh, Gyeong-Won Lee, Won-Sik Lee, Deok-Hwan Yang, Young Rok Do, Min Kyoung Kim, Kwai Han Yoo, Yoon Seok Choi, Hwan Jung Yun, Jun Ho Yi, Jae-Cheol Jo, Hyeon-Seok Eom, Jae-Yong Kwak, Ho-Jin Shin, Byeong Bae Park, Shin Young Hyun, Seong Yoon Yi, Ji-Hyun Kwon, Sung Yong Oh, Hyo Jung Kim, Byeong Seok Sohn, Jong Ho Won, Se-Hyung Kim, Ho-Sup Lee, Cheolwon Suh, Won Seog Kim
Cancer Res Treat. 2022;54(4):1268-1277. Published online December 30, 2021
Purpose
Febrile neutropenia (FN) can cause suboptimal treatment and treatment-related mortality (TRM) in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP).
Materials and methods
We conducted a prospective cohort study to evaluate the effectiveness of pegfilgrastim prophylaxis in DLBCL patients receiving R-CHOP, and we compared them with the PROCESS cohort (n=485).
Results
Since January 2015, 986 patients with DLBCL were enrolled. Pegfilgrastim was administered at least once in 930 patients (94.3%), covering 90.3% of all cycles. FN developed in 137 patients (13.9%) in this cohort (23.7% in the PROCESS cohort, p<0.001), and 4.2% of all cycles (10.2% in the PROCESS cohort, p<0.001). Dose delay was less common (≥3 days: 18.1% vs. 23.7%, p=0.015; ≥5 days: 12.0% vs. 18.3%, p=0.023) in this cohort than in the PROCESS cohort. The incidence of TRM (3.2% vs. 5.6%, p=0.047) and infection-related death (1.8% vs. 4.5%, p=0.004) was lower in this cohort than in the PROCESS cohort. The 4-year overall survival (OS) and progression-free survival (PFS) rates of the two cohorts were not different (OS: 73.0% vs. 71.9%, p=0.545; PFS: 69.5% vs. 68.8%, p=0.616). However, in patients aged ≥75 years, the 4-year OS and PFS rates were higher in this cohort than in the PROCESS cohort (OS: 49.6% vs. 33.7%, p=0.032; PFS: 44.2% vs. 30.3% p=0.047).
Conclusion
Pegfilgrastim prophylaxis is effective in the prevention of FN and infection-related death in DLBCL patients receiving R-CHOP, and it also improves OS in patients aged ≥75 years.
Eo Jin Kim, Yong-Hee Cho, Dong Ha Kim, Dae-Hyun Ko, Eun-Ju Do, Sang-Yeob Kim, Yong Man Kim, Jae Seob Jung, Yoonmi Kang, Wonjun Ji, Myeong Geun Choi, Jae Cheol Lee, Jin Kyung Rho, Chang-Min Choi
Cancer Res Treat. 2022;54(4):1005-1016. Published online December 3, 2021
Purpose The aim of this study is to evaluate the safety and efficacy of ex vivo activated and expanded natural killer (NK) cell therapy (SNK01) plus pembrolizumab in a randomized phase I/IIa clinical trial.
Materials and Methods Overall, 18 patients with advanced non–small cell lung cancer (NSCLC) and a programmed death ligand 1 tumor proportion score of 1% or greater who had a history of failed frontline platinum-based therapy were randomized (2:1) to receive pembrolizumab every 3 weeks +/– 6 weekly infusions of SNK01 at either 2×109 or 4×109 cells per infusion (pembrolizumab monotherapy vs. SNK01 combination). The primary endpoint was safety, whereas the secondary endpoints were the objective response rate (ORR), progression-free survival (PFS), overall survival, and quality of life.
Results Since no dose-limiting toxicity was observed, the maximum tolerated dose was determined as SNK01 4×109 cells/dose. The safety data did not show any new safety signals when SNK01 was combined with pembrolizumab. The ORR and the 1-year survival rate in the NK combination group were higher than those in patients who underwent pembrolizumab monotherapy (ORR, 41.7% vs. 0%; 1-year survival rate, 66.7% vs. 50.0%). Furthermore, the median PFS was higher in the SNK01 combination group (6.2 months vs. 1.6 months, p=0.001).
Conclusion Based on the findings of this study, the NK cell combination therapy may consider as a safe treatment method for stage IV NSCLC patients who had a history of failed platinum-based therapy without an increase in adverse events.
Citations
Citations to this article as recorded by
Safety and efficacy of SNK01 (autologous natural killer cells) in combination with cytotoxic chemotherapy and/or cetuximab after failure of prior tyrosine kinase inhibitor in non-small cell lung cancer: non-clinical mouse model and phase I/IIa clinical st Myeong Geun Choi, Gun Woo Son, Mi Young Choi, Jae Seob Jung, Jin Kyung Rho, Wonjun Ji, Byeong Gon Yoon, Jong-Min Jo, Yong Man Kim, Dae-Hyun Ko, Jae Cheol Lee, Chang-Min Choi Journal for ImmunoTherapy of Cancer.2024; 12(3): e008585. CrossRef
Disruption of TGF-β signaling pathway is required to mediate effective killing of hepatocellular carcinoma by human iPSC-derived NK cells Jaya Lakshmi Thangaraj, Michael Coffey, Edith Lopez, Dan S. Kaufman Cell Stem Cell.2024; 31(9): 1327. CrossRef
Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy Xin Su, Jian Li, Xiao Xu, Youbao Ye, Cailiu Wang, Guanglong Pang, Wenxiu Liu, Ang Liu, Changchun Zhao, Xiangyong Hao Journal of Translational Medicine.2024;[Epub] CrossRef
Epigenetic regulation of NKG2D ligand and the rise of NK cell-based immunotherapy for cancer treatment Raj Kumar, Romi Gupta Frontiers in Oncology.2024;[Epub] CrossRef
Efficacy and safety of natural killer cell therapy in patients with solid tumors: a systematic review and meta-analysis Heesook Park, Gyurin Kim, Najin Kim, Sungyoen Ha, Hyeonwoo Yim Frontiers in Immunology.2024;[Epub] CrossRef
Next-generation immunotherapy: igniting new hope for lung cancer Molly S. C. Li, Andrew L. S. Chan, Kevin K. S. Mok, Landon L. Chan, Tony S. K. Mok Therapeutic Advances in Medical Oncology.2024;[Epub] CrossRef
Engineered Cellular Therapies for the Treatment of Thoracic Cancers Spencer M. Erickson, Benjamin M. Manning, Akhilesh Kumar, Manish R. Patel Cancers.2024; 17(1): 35. CrossRef
Cellular Therapy in NSCLC: Between Myth and Reality Martina Imbimbo, Laureline Wetterwald, Alex Friedlaender, Kaushal Parikh, Alfredo Addeo Current Oncology Reports.2023; 25(10): 1161. CrossRef
NK cell activity and methylated HOXA9 ctDNA as prognostic biomarkers in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors Sara Witting Christensen Wen, Line Nederby, Rikke Fredslund Andersen, Torben Schjødt Hansen, Christa Haugaard Nyhus, Ole Hilberg, Anders Jakobsen, Torben Frøstrup Hansen British Journal of Cancer.2023; 129(1): 135. CrossRef
Harnessing Natural Killer Cells for Lung Cancer Therapy Shoubao Ma, Michael A. Caligiuri, Jianhua Yu Cancer Research.2023; 83(20): 3327. CrossRef
Natural killer cells: the next wave in cancer immunotherapy Xin Chen, Lei Jiang, Xuesong Liu Frontiers in Immunology.2022;[Epub] CrossRef
Sang Eun Yoon, Yeon Jeong Kim, Joon Ho Shim, Donghyun Park, Junhun Cho, Young Hyeh Ko, Woong-Yang Park, Yeung-Chul Mun, Kyoung Eun Lee, Duck Cho, Won Seog Kim, Seok Jin Kim
Cancer Res Treat. 2022;54(2):597-612. Published online July 23, 2021
Purpose
Analysis of circulating tumor DNA (ctDNA) in blood could allow noninvasive genetic analysis of primary tumors. Although there have been unmet needs for noninvasive methods in patients with primary central nervous system lymphoma (PCNSL), it is still not determined whether plasma ctDNA analysis could be useful for patients with PCNSL.
Materials and Methods
Targeted deep sequencing of 54 genes was performed in cell-free DNA isolated from plasma samples collected pretreatment, during treatment, and at the end of treatment in 42 consecutively diagnosed PCNSL patients between January 2017 and December 2018.
Results
Targeted sequencing of plasma cell-free DNA detected somatic mutations representing ctDNA in 11 cases (11/41, 27%). The detection of ctDNA was not related to the concentration of cell-free DNA or tumor volume. The mutation profiles of these 11 cases varied between patients. The most frequently mutated gene was PIM1 (4/11, 36.4%), whereas KMT2D, PIK3CA, and MYD88 were each observed in three patients (3/11, 27%). The mutations of 13 genes were concordantly found in primary tumor tissue and plasma ctDNA, giving a detection sensitivity of 45%. During the serial tracking of seven patients with complete response, the disappearance of ctDNA mutations was found in four patients, whereas three patients had detected ctDNA mutation at the end of treatment.
Conclusion
The plasma ctDNA mutation analysis still has limited value for surveillance and predicting treatment outcomes of PCNSL because the detection efficiency was lower than other systemic lymphomas. Thus, analytical platforms should be improved to overcome anatomical hurdles associated with PCNSL.
Citations
Citations to this article as recorded by
Feasibility of Circulating Tumor DNA Detection in the Cerebrospinal Fluid of Patients With Central Nervous System Involvement in Large B-Cell Lymphoma Seok Jin Kim, Jin Ju Kim, Mi Ri Park, Bon Park, Kyung Ju Ryu, Sang Eun Yoon, Won Seog Kim, Saeam Shin, Seung-Tae Lee Annals of Laboratory Medicine.2025; 45(1): 90. CrossRef
Detection of circulating tumor DNA in plasma of patients with primary CNS lymphoma by digital droplet PCR Yujie Zhong, Geok Wee Tan, Johanna Bult, Nick Veltmaat, Wouter Plattel, Joost Kluiver, Roelien Enting, Arjan Diepstra, Anke van den Berg, Marcel Nijland BMC Cancer.2024;[Epub] CrossRef
Clinical implications of CSF-ctDNA positivity in newly diagnosed diffuse large B cell lymphoma Jin-Hua Liang, Yi-Fan Wu, Hao-Rui Shen, Yue Li, Jun-Heng Liang, Rui Gao, Wei Hua, Chun-Yu Shang, Kai-Xin Du, Tong-Yao Xing, Xin-Yu Zhang, Chen-Xuan Wang, Liu-Qing Zhu, Yang W. Shao, Jian-Yong Li, Jia-Zhu Wu, Hua Yin, Li Wang, Wei Xu Leukemia.2024; 38(7): 1541. CrossRef
Liquid biopsy for improving diagnosis and monitoring of CNS lymphomas: A RANO review Lakshmi Nayak, Chetan Bettegowda, Florian Scherer, Norbert Galldiks, Manmeet Ahluwalia, Alexander Baraniskin, Louisa von Baumgarten, Jacoline E C Bromberg, Andrés J M Ferreri, Christian Grommes, Khê Hoang-Xuan, Julia Kühn, James L Rubenstein, Roberta Rudà Neuro-Oncology.2024; 26(6): 993. CrossRef
Feasibility of Circulating Tumor DNA Analysis in Patients with Follicular Lymphoma Sang Eun Yoon, Seung-Ho Shin, Dae Keun Nam, Junhun Cho, Won Seog Kim, Seok Jin Kim Cancer Research and Treatment.2024; 56(3): 920. CrossRef
Clinical applications of circulating tumor DNA in hematological malignancies: From past to the future Jun-Ying Li, Li-Ping Zuo, Jian Xu, Chun-Yan Sun Blood Reviews.2024; 68: 101237. CrossRef
Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas Jurik A. Mutter, Stefan K. Alig, Mohammad S. Esfahani, Eliza M. Lauer, Jan Mitschke, David M. Kurtz, Julia Kühn, Sabine Bleul, Mari Olsen, Chih Long Liu, Michael C. Jin, Charles W. Macaulay, Nicolas Neidert, Timo Volk, Michel Eisenblaetter, Sebastian Raue Journal of Clinical Oncology.2023; 41(9): 1684. CrossRef
Clinical applications of circulating tumor DNA in central nervous system lymphoma Anna Katharina Foerster, Eliza M. Lauer, Florian Scherer Seminars in Hematology.2023; 60(3): 150. CrossRef
Genetic Profiling of Cell-Free DNA in Liquid Biopsies: A Complementary Tool for the Diagnosis of B-Cell Lymphomas and the Surveillance of Measurable Residual Disease Gloria Figaredo, Alejandro Martín-Muñoz, Santiago Barrio, Laura Parrilla, Yolanda Campos-Martín, María Poza, Laura Rufián, Patrocinio Algara, Marina De La Torre, Ana Jiménez Ubieto, Joaquín Martínez-López, Luis-Felipe Casado, Manuela Mollejo Cancers.2023; 15(16): 4022. CrossRef
Asian variant intravascular large B-cell lymphoma with highly suspected central nervous system involvement: A case report Yong-Pyo Lee, Seung-Myoung Son, Jihyun Kwon World Journal of Clinical Cases.2023; 11(33): 8058. CrossRef
The Minimal Residual Disease Using Liquid Biopsies in Hematological Malignancies Rafael Colmenares, Noemí Álvarez, Santiago Barrio, Joaquín Martínez-López, Rosa Ayala Cancers.2022; 14(5): 1310. CrossRef